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ABSTRACT 
  Cardiac muscle contraction is responsible for pumping blood throughout the 
body. The cyclical, ATP-hydrolysis dependent interaction of the myosin motor 
protein with filamentous actin drives muscle contraction. During this process the 
α-helical neck region of myosin acts as a lever arm, transmitting contractile force 
between thick and thin filaments by amplifying small conformational changes in the 
myosin motor domain. The resulting relative displacement of thick and thin 
filaments causes muscle shortening. The regulatory light chain (RLC) of myosin 
mechanically supports the lever arm by binding to the myosin heavy chain neck 
region; this is a crucial interaction in maintaining myosin’s ability to produce force 
and motion. We investigated the role of N-terminal modifications of the RLC in 
modulating actomyosin contractility at the molecular level. Phosphorylation of the 
RLC is a naturally occurring post-translational modification of the RLC N-terminus 
that is important for cardiac function and has been shown to enhance contractility 
at the cellular level. In contrast, genetic mutations of the RLC that lead to familial 
  
vii 
hypertrophic cardiomyopathy (FHC) disrupt cardiac function and trigger 
remodeling of the cardiac muscle structure. We studied two FHC-linked mutations, 
N47K and R58Q, located in the N-terminus of the RLC in close proximity to the 
phosphorylation site. Using in vitro motility assays we examined how RLC 
modifications affect the mechanochemical properties of cardiac β-myosin. We 
found that the FHC mutations reduced myosin force and power generation, in 
contrast to RLC phosphorylation which increased myosin force and power for WT 
and mutant myosins.  Phosphorylation of mutant RLC resulted in a restoration of 
the mutation-induced decreases in contractility to WT dephosphorylated levels. 
These results point to RLC phosphorylation as a general mechanism to increase 
force production of the individual myosin motor and as a potential target to 
ameliorate the fundamental contractile FHC-induced phenotype.  
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CHAPTER 1 – INTRODUCTION 
 
1.1 Significance and Scope of this Thesis 
  My overall goal as a researcher in basic science is to understand the 
mechanisms of cardiac muscle contraction and how these processes are altered 
in disease. The studies presented in this thesis are focused on the regulatory 
light chain (RLC) of myosin. Myosin is the motor protein directly responsible for 
generating the force and motion of muscle contraction by using the chemical 
energy from ATP 
hydrolysis to translocate 
actin thin filaments. The 
RLC binds to the S1-S2 
junction of myosin in a 
position where it can 
interact with and influence 
the thick filament 
ensemble of myosins, as 
well as the individual myosin protein (Figure 1.1). The aim of my dissertation is to 
understand how modifications of the RLC modulate cardiac muscle contraction at 
the molecular level.  Specifically, I studied phosphorylation of the RLC and two 
genetic mutations of the RLC which lead to cardiac disease.  
Figure 1.1: RLC Binds to S1-S2 Junction of Myosin 
Myosin molecules oligomerize to form a thick filament 
ensemble. Myosin subfragment 1 (S1) consists of a motor 
domain, an essential light chain (ELC), and a regulatory 
light chain (RLC). Myosin subfragment 2 (S2) is part of 
the rod domain which forms the thick filament backbone. 
Adapted from [140]. 
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  Phosphorylation of the RLC is a naturally occurring post-translation 
modification that is critical to the proper functioning heart. RLC phosphorylation is 
constitutively maintained at about 50% in the heart and modulates cardiac 
contraction; however, the mechanism by which it exerts its effects is not fully 
understood. In skeletal muscle fibers, RLC phosphorylation is correlated with 
potentiation of the isometric force response [134], and in vitro studies indicate 
that it alters myosin thick filament structure presumably by repelling myosin 
heads away from the thick filament [69]. Phosphorylation of the RLC has also 
been associated with changes in the stiffness of the lever arm and/or hinge 
region in skeletal [42] and smooth [64] muscle myosins. Understanding the 
molecular mechanism of RLC phosphorylation is important because 
phosphorylation levels are often altered in disease [56, 86, 142, 146]. 
Cardiomyopathy is a condition where the heart muscle is structurally or 
functionally abnormal. Two cardiomyopathy-linked mutations, N47K and R58Q, 
located in the RLC N-terminus are studied in this work. Previously, both 
mutations have been shown to disrupt the load-dependent behavior of cardiac 
myosin [41]. Because of the opposing effects of phosphorylation and the RLC 
mutations, I have tested the hypothesis that phosphorylation of the mutant RLC 
rescues mutation-induced defects in the myosin molecule.  
  I investigated the effect of RLC mutations and phosphorylation on myosin 
contractility at the molecular level using in vitro motility assays with an applied 
exogenous load to gain a better understanding of how RLC modifications can 
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lead to the effects and phenotypes that are observed at the organ level. I found 
that RLC mutations reduced the force generating capabilities of isolated cardiac 
myosin, while phosphorylation of the RLC enhanced the force producing ability of 
WT myosin, as well as that of the mutant myosins. The enhanced force 
production of mutant myosins in the phosphorylated state resulted in a 
restoration of force production to WT dephosphorylated levels. 
 
Note to the reader: Unless otherwise noted, the information provided in sections 
1.2.1, 1.2.2, and 1.3.1 can be found in the following textbooks: “Muscle 
Contraction” by Bagshaw 1993, and “Physiology of the Heart & Circulation” by 
Little 1981. The reader is referred to these texts for further information.  
 
1.2 Muscle Contraction 
  There are three types of muscle tissue in the human body: skeletal, 
smooth, and cardiac muscle. Regardless of the type, all muscles contract, 
producing force and motion. Skeletal muscle is attached to bones by tendons, 
and is responsible for moving the skeleton. Although skeletal muscle has many 
functions ranging from rapid body movement to maintaining posture, it is 
voluntarily controlled. Smooth muscle is found lining the walls of many hollow 
organs, blood vessels and respiratory passageways and is responsible for 
changes in organ shape and internal organ movements such as peristaltic 
contractions during digestion and pupil dilation. Cardiac muscle is found 
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exclusively in the walls of the heart, and is responsible for pumping blood through 
the circulatory system. Smooth and cardiac muscle contraction is involuntary. 
  The focus of this thesis is on contractile proteins isolated from cardiac 
muscle. In the following sections of this chapter, I will introduce the cardiac 
muscle cell, basic properties of muscle contraction, the structure-function 
relationship of the heart and how it is affected by RLC phosphorylation and FHC 
mutations. 
 
1.2.1 Cardiac Muscle Histology 
   Cardiac muscle cells, also called fibers or myocytes, are elongated, thin 
and branched. Due to their branched nature and end-to-end connections cardiac 
muscle cells form an intertwined directional fibrous mesh that comprises the 
muscle tissue of the heart (Figure 1.2). The sarcolemma is the cell membrane 
that surrounds each fiber and is responsible for the end-to-end connection by 
forming intercalated discs at the junction of two cells. Intercalated discs consist of 
over lapping finger-like protrusions of the sarcolemma that contain desmosomes 
which create strong cell-cell adhesions, fascia adherens which anchor internal 
cellular structures to the membrane, and numerous gap junctions which directly 
connect the cytoplasm of neighboring cells facilitating the rapid spread of an 
electrical signal from cell to cell. Intercalated discs are only found in cardiac 
muscle cells, and allow depolarization to spread throughout the cardiac tissue to 
create the synchronized pumping action of the tissue while preventing adjoining 
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cells from separating under the shear stress of contraction. 
 
  The cytoplasm of cardiac muscle fibers largely consists of myofibrils, 
highly specialized cylindrical organelles that span the length of the cell. Myofibrils 
are responsible for the physical contraction of muscle cells (Figure 1.3). The 
characteristic light and dark banding pattern of single myofibril results from a 
repeating structural unit called a sarcomere (Figure 1.3). Each sarcomere is a 
highly organized array of overlapping thick and thin filaments that shortens and 
lengthens as the thick and thin filaments slide relative to each other. 
Synchronized contraction of sarcomeres within the myofibrils results in the large 
scale contraction of the muscle fiber.  
  Muscle contraction is activated by calcium binding to the thin filament 
(Figure 1.6). The simultaneous contraction of parallel-arranged myofibrils within a 
Figure 1.2: Cartoon Depicting Cellular Arrangement of Cardiac Muscle Tissue 
The myocardium is composed of branched muscle fibers that adjoin to neighboring cells 
at intercalated discs which are perpendicular to the long axis of the fiber. Figure from 
http://www.highlands.edu/academics/divisions/scipe/biology/labs/cartersville/2122/diagr
ams/heartdiagram3.jpg and http://www.britannica.com/science/heart/images-videos. 
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muscle fiber is triggered by a large scale release of calcium into the cytoplasm. 
When an action potential is initiated in a cardiac muscle cell, calcium is released 
into the cytoplasm from regularly spaced invaginations in the sarcolemma known 
as t-tubules (Figure 1.3). The calcium released from t-tubules is not sufficient to 
activate the muscle, but this initial calcium release triggers the release of large 
stores of calcium from within the sarcoplasmic reticulum, an extensive network of 
tubules that surrounds each myofibril and is responsible for storing, releasing, 
and sequestering calcium in the course of the activation-relaxation cycle during 
the heartbeat (Figure 1.3). The sarcoplasmic network assures that calcium is 
released throughout the whole cell thus activating contraction simultaneously 
along the entire length of the fiber. 
 
Figure 1.3: Components of Cardiac Muscle Cells 
The diagram shows the arrangement of organelles within a cardiomyocyte. A 
cardiomyocyte has a single nucleus which is located near the center of the cell, and 
myofibrils which span the length of the cell. Myofibrils are comprised of a highly ordered 
repeating unit called a sarcomere which give the cell a striated appearance. Figure from 
http://www.imagekb.com/myocardium 
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  The heart is the most worked muscle in the body, continually contracting 
to pump blood ~70 times/min over a lifetime, and therefore requires a constant 
source of energy. For this reason, cardiac muscle cells have an extremely high 
mitochondrial density in between myofibrils which allow the cell to quickly supply 
large amounts of ATP to adjacent sarcomeres, where the chemical energy from 
the hydrolysis of ATP is converted into kinetic energy in the form of muscle 
contraction.  
 
1.2.2 Sarcomere: The Contractile Unit 
   The banding pattern observed in striated muscle results from the series 
arrangement of cylindrical structures called sarcomeres, the fundamental 
contractile units of muscle. Each sarcomere consists of a parallel lattice of 
interdigitated thick and thin filaments held in place between two Z-discs, which 
form boundaries between neighboring sarcomeres (Figure 1.4). Thin filaments 
contain primarily actin and are anchored directly to the Z-disc, which is 
comprised primarily of α-actinin, an actin binding protein. Actin filaments extend 
from the Z-disc towards the center of the sarcomere. The motor protein myosin 
forms bipolar thick filaments, the center of which attach to a protein scaffold at 
the midline of the sarcomere. Each end of the thick filament is tethered to the 
nearest Z-disc by a large elastic protein called titin. Opposite ends of thick 
filaments are inserted into the lattice of thin filaments that attach and extend from 
the nearest Z-disc. The array of thick and thin filaments reveals a highly defined 
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myofilament lattice when viewed in cross-section. In the overlapping region of 
myofilaments, the thin filaments form a hexagonal arrangement around each 
thick filament, and in turn thick filaments form a triangular arrangement around 
each thin filament (Figure 1.4).  
 
  Myosin forms cross-bridges that extend from the thick filament backbone 
which interact with actin in the thin filaments to shorten the sarcomere. Thick 
filament cross-bridges pull the thin filaments towards the center of the 
sarcomere, increasing the level of filament overlap and moving both Z-discs 
closer together.  Thick filaments are 1.6 μm long, thin filaments are 0.8 μm long, 
Figure 1.4: Sarcomere Structure 
The sarcomere consists of an interdigitating array of thick and thin filaments that lie 
between two Z-discs. Myosin cross-bridges protruding from bipolar thick filaments pull 
thin filaments towards the M-line causing the sarcomere to contract. The distance
between two Z-discs ranges from about 1.6 to 2.2 m. A cross sectional view of the thick 
and thin filament overlap region shows the myofilament lattice arrangement. Adapted 
from http://droualb.faculty.mjc.edu/Course%20Materials/Elementary%20Anatomy%20 
and%20Physiology%2050/Lecture%20outlines/skeletal_muscle_physiology.htm 
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and the sarcomere is approximately 2 μm long at rest [112]. During cardiac 
contraction the sarcomere will shorten by up to 20% [14] or about 400 nm. Given 
that sarcomeres in a single myofibril are connected in series, a small sarcomeric 
length change will produce a significant shortening of the myofibril and muscle 
fiber.  
 
Figure 1.5: Thick and Thin Filament Structure 
Myosin molecules arrange in a bipolar fashion at the center of the thick filament, forming 
a bare zone where no cross-bridges are present. Myosin heads protrude off the backbone 
in a helical orientation away from the bare zone. Myosin binding protein C (MyBP-C) 
binds next to myosin heads in the inner third of the thick filament. Thick filaments are 
approximately 3 times wider than thin filaments. Thin filaments are comprised of 
filamentous actin decorated with tropomyosin and troponin. A tropomyosin molecule
binds to seven actin monomers. Tropomyosins form end to end bonds to wrap around 
the entire length of the filament. A troponin complex binds to each tropomyosin molecule. 
When troponin binds calcium it moves off the actin filament and tropomyosin shifts 
position to expose myosin binding sites. 
Adapted from http://cdn2.fitforlife.fr/wp-content/uploads/2014/01/myosin-actin.jpg, 
http://users.atw.hu/blp6/BLP6/HTML/S3.htm,https://classconnection.s3.amazonaws.
com/67582/flashcards/670169/png/thick-filaments-called-myosin.png, 
https://classconnection.s3.amazonaws.com/959/flashcards/1239959/jpg/thin_filaments1
350281212582.jpg 
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Thick Filament Structure 
   Myosin is composed of a long rod-like domain connected to a globular 
domain at one end. Myosin rod domains oligomerize in a parallel, staggered 
fashion to form the thick filament backbone while the globular domains sit at the 
surface of the thick filament and form the cross-bridges. Myosin molecules 
arrange in a bipolar fashion at the center of a thick filament with their rod 
domains aligned in an anti-parallel orientation; this creates a bare zone at the 
mid-region of the filament that is devoid of cross-bridges (Figure 1.5). Another 
protein associated with the thick filament is myosin binding protein C (MyBP-C), 
which binds next to myosin cross-bridges along the inner third of the thick 
filament. MyBP-C also extends off the thick filament to interact with actin and is 
thought to have a modulatory role in muscle contraction.  
 
Thin Filament Structure 
  There are three main proteins that comprise the thin filament: actin, 
tropomyosin, and troponin (Figure 1.5). Actin monomers polymerize into a 
filament which forms the core of the thin filament. Tropomyosin is an α-helical 
coiled-coil protein that binds along the actin filament spanning seven consecutive 
actin monomers. Tropomyosins form end to end bonds to create a ropelike 
structure that winds around the entire actin filament [105]. Troponin is a calcium 
binding protein that, together with tropomyosin, regulates the activation of muscle 
contraction. A troponin complex binds along each tropomyosin and spans the 
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junction of two tropomyosin molecules [131]. In the absence of calcium, troponin 
also binds to actin such that it forces tropomyosin to assume a position on actin 
that sterically blocks myosin binding sites [101]. When troponin binds calcium 
during muscle activation, it dissociates from actin which allows tropomyosin to 
assume its preferred position on actin, exposing myosin binding sites and 
allowing muscle contraction to proceed (for review see [39]).  
  The above  regulatory scheme is known as the steric blocking model 
(Figure 1.6), where tropomyosin position on actin is in equilibrium between three 
states (a blocked, closed, and open state) [78]. In the absence of calcium, 
tropomyosin assumes a “blocked” position on actin and prevents myosin-binding. 
In the presence of calcium, tropomyosin favors a “closed” position on actin that 
partially exposes the myosin-binding site and allows the myosin cross-bridge to 
weakly bind actin. When myosin weakly binds the thin filament, the tropomyosin 
strand shifts even further to fully expose myosin-binding sites, such that 
tropomyosin assumes an “open” position on actin. In an open state, the myosin 
cross-bridge is able to undergo a weak to strong binding transition [24]. By 
moving tropomyosin to a fully open state, myosin binding lowers the energy 
barrier for neighboring myosins to bind actin, and therefore increases the 
probability that successive cross-bridges will bind to the thin filament. The effects 
of myosin binding are more pronounced when the thin filament is only partially 
activated by calcium. This provides an influential role for the strong binding of 
myosin in regulating muscle contraction, although calcium activation of the thin 
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filament remains a requirement of regulation. While thin filament regulation may 
be the dominant control process in striated muscle, the focus of this thesis is on 
thick filament-based regulation, which modulates muscle contractility further. 
 
1.2.3 Myosin  
  Myosin motors are the molecular machinery responsible for converting the 
energy from ATP hydrolysis into the force and motion of muscle contraction. 
Myosin is a hexameric protein made up of two myosin heavy chains (MHC), two 
essential light chains (ELC) and two regulatory light chains (RLC).  The MHC has 
an N-terminal globular head domain, an α-helical neck region and a C-terminal 
tail domain (Figure 1.7). The tail domain is responsible for dimerization of the 
MHCs, forming an α-helical coiled-coil rod that composes the backbone of 
myosin thick filaments.  The ELC and RLC bind to the α-helical neck region of 
each MHC. The myosin heavy chain globular head along with the light chain 
 
Figure 1.6: Three State Model of Regulation 
Tropomyosin position on actin is in equilibrium between three states. Equilibrium 
between the blocked and closed states (KB) is mediated by calcium, while the equilibrium 
between closed and open states (KT) can be mediated by calcium or myosin binding.
This figure is based on the kinetic scheme put forth by McKillop and Geeves [78].  
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bound neck region constitute the myosin cross-bridge that protrudes off the 
filament backbone, and is commonly referred to as subfragment 1 (S1) due to 
proteolytic digestion sites (Figure 1.7). The globular head comprises the catalytic 
motor domain of myosin which contains an actin binding site and an ATP binding 
site. 
 
 
 
Figure 1.7: Myosin Structure  
The cartoon shows full length myosin which consists of the two myosin heavy chains 
(MHC), two essential light chains (ELC) and two regulatory light chains (RLC). Protease 
sites and resulting fragments are labeled. Adapted from 
http://users.atw.hu/blp6/BLP6/HTML/S3.htm. The x-ray crystallographic structure of 
chicken skeletal myosin S1 is shown with labeled domains (PDB ID: 2MYS).  
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  Myosin binds to actin, displaces actin, and dissociates from actin as it 
hydrolyzes ATP [73]. The light chain bound neck region of myosin acts as a lever 
arm to amplify small conformational changes that occur in the catalytic site and 
generate a large scale displacement of actin [145]. The converter domain is a 
small compact structure that sits at the junction of the catalytic motor domain and 
the lever arm. The converter rotates relative to the motor domain as myosin 
occupies different nucleotide bound states (Figure 1.8). The lever arm, linked 
directly to the converter, swings through a ~70° angle to produce a displacement 
of actin that is proportional to the length of the lever arm [107]. This 
conformational rearrangement of the myosin cross-bridge is called the myosin 
powerstroke. The lever arm must be somewhat rigid to transmit contractile force 
from the actin-bound head to the thick filament backbone. Binding of the ELC 
and RLC to the single α-helix of the MHC neck region mechanically stabilizes the 
lever arm [84]. In the absence of bound light chains, the α-helical neck is 
insufficient to transmit contractile force, and the lever arm is essentially reduced 
to the length of the converter-catalytic domain linkage, resulting in significantly 
decreased actin displacements [144]. 
 
             
Figure 1.8: Myosin Powerstroke 
A ~70° rotation of the converter domain relative to the motor domain results in a structural 
rearrangement of myosin that displaces the bound actin filament. The myosin lever arm 
rotates with the converter domain to amplify the displacement of actin. Adapted from [33].
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  In mammalian hearts there are two genes (MYH6 and MYH7) that encode 
the MHC which results in the expression of two distinct MHC isoforms (α and β, 
respectively) [92]. In the human myocardium, the β-MHC isoform is dominantly 
expressed. Each light chain of myosin is also encoded by two genes in cardiac 
tissue. The ELC is encoded by the MYL3 and MYL4 genes, and the RLC is 
encoded by the MYL7 and MYL2 genes. The MYL3 and MYL7 genes are 
exclusively expressed in the atrial myocardium while the MYL4 and MYL2 genes 
are exclusively expressed in the ventricular myocardium; this results in an atrial 
and ventricular isoform for each light chain. Genetic mutations linked to 
cardiomyopathies have been identified in the genes that encode the MHC 
isoforms and the ventricular light chain isoforms [79, 89]. It is of note that 
cardiomyopathy-linked mutations associated with the MYH6 gene are rare with a 
total of 5 documented cases [15, 94] while mutations in the MYH7 gene are the 
most frequent cause of hypertrophic cardiomyopathy [3]. The work carried out in 
this thesis was focused on the β-MHC and ventricular RLC isoforms. 
  The ELC and RLC are calmodulin homology proteins, each containing two 
globular domains connected by a flexible linker that wraps around the α-helical 
neck forming a dumbbell shape [9, 19]. Both light chains contain four EF hand 
motifs however in each light chain only one of the EF hands is capable of cation 
binding. The ELC binds to a conventional IQ motif allowing overlap of its two 
lobes when bound to the MHC, however the RLC binds to a modified IQ motif 
that allows each lobe to bind in tandem, expanding the range of the MHC that is 
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stabilized by the RLC [51]. The RLC binds to the C-terminus of the lever arm, 
sitting at the junction of the lever arm and rod domain of the filament backbone 
(Figure 1.9). The MHC α-helix forms a hook at this junction, and the modified IQ 
motif allows the RLC to bind both sides of the sharp bend [51]. This region acts 
as a pivot to allow the lever arm to change orientations relative to the filament 
backbone as myosin performs its powerstroke. Therefore in addition to providing 
structural support to the lever arm, the RLC also binds to a critical hinge region of 
the lever arm and interfaces with the thick filament backbone. 
  The RLC N-terminal lobe 
binds to the C-terminus of the 
lever arm surrounding the hinge 
region (Figure 1.9), and the C-
terminal lobe binds further up the 
lever interfacing with the ELC 
[106]. New evidence suggests 
that the functional pivot point of 
the lever arm may lie between 
the RLC N- and C-lobes [61]. 
Studies in this thesis focus on N-
terminal modifications of the 
ventricular myosin RLC. The 
RLC contains an EF hand motif 
 
Figure 1.9: Regulatory Light Chain 
The N- and C-terminal lobes of the RLC bind 
adjacent segments of the sharp hook of the MHC. 
The N-lobe binds at the junction of the lever arm 
and rod domain. The positon of the cation binding 
site, the phosphorylation site and two 
cardiomyopathy-linked mutations are shown 
(PDB ID: 2MYS).  
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capable of binding Ca2+–Mg2+ and a highly conserved phosphorylation site at 
serine15 in its N-terminal lobe. The RLC undergoes structural changes upon 
cation binding [108, 139]. The cation binding site could be involved in regulating 
Ca2+ levels in muscle cells [1] or possibly serve a structural role [108].  The RLC 
phosphorylation site is in close proximity to the cation binding site, and in skeletal 
muscle phosphorylation induces a conformational change of the RLC [111]. In 
smooth muscle, RLC phosphorylation activates muscle contraction, but in 
striated muscle it is thought to exert a modulatory role. The role of RLC 
phosphorylation in the heart will be discussed in detail in section 1.3.3.  
 
1.2.4 Acto-Myosin Biochemical Cycle 
  The classic Lymn-Taylor model [73] correlates the biochemical and 
mechanical intermediates of the actomyosin cross-bridge cycle (Figure 1.10). 
The time it takes to complete one biochemical cycle is the inverse of the actin-
activated ATPase rate of myosin, kATP (=1/tcycle). Myosin is detached from actin 
when it has ATP bound in its active site. The myosin cross-bridge hydrolyzes 
ATP which primes the head for actin-binding allowing myosin to weakly interact 
with the thin filament. The myosin head undergoes a weak to strong binding 
transition which is coupled to the release of inorganic phosphate and a 
conformational rearrangement of the lever arm. This is known as the myosin 
powerstroke and results in actin filament displacement by a distance, d (Figure 
1.10). ADP is released from the cross-bridge and myosin remains tightly bound 
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to actin in a post-powerstroke rigor state until ATP binding causes rapid 
dissociation of the actomyosin complex.
 
  The rate limiting step of actomyosin detachment is ADP release. EM 
reconstructions and crystal structures of S1 with different nucleotides bound 
suggest that ADP release is associated with a continuation of the lever arm 
swing of the myosin powerstroke [10, 59, 113, 114, 157], albeit much smaller in 
magnitude than the lever arm swing associated with phosphate release. The 
amount of time that myosin spends in the ADP-bound and rigor states 
determines how long it is strongly attached to actin, ton. Myosin can only produce 
force in a strongly bound state. The fraction of time that myosin spends strongly 
attached during one biochemical cycle is known as the duty cycle, f (=ton/tcycle). 
Force production can be tuned by changing the rates of cross-bridge attachment 
 
 
Figure 1.10: Actomyosin Cross-bridge Cycle 
Myosin weakly binds an actin filament when ADP and phosphate occupy the nucleotide 
binding pocket. The myosin powerstroke is coupled to the release of phosphate, and 
results in the displacement of actin by a distance, d. Myosin is strongly bound to actin in 
the ADP bound and rigor states. The time myosin spends strongly bound to actin during 
one cycle is ton. Figure from Jeff Moore. 
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or detachment to influence the population of myosin cross-bridges occupying a 
strong binding state. 
  Mammalian hearts express α- and β- MHC isoforms. In humans, the atrial 
myocardium predominantly expresses α-MHC, while in the ventricular 
myocardium β-MHC is dominantly expressed at a 9:1 ratio over the α-isoform, 
although the ratios of α- and β-MHC shift during disease [82, 109]. The difference 
in isoform expression is significant because the MHC isoforms exhibit different 
functional properties. The α-MHC displays faster ATPase rates and shortening 
velocities, however, slower cross-bridge cycling of the β-MHC allows for higher 
levels of force generation in a more energetically efficient manner [47, 117, 147]. 
Single molecule optical trapping studies have shown that β-myosin has a 
prolonged rate of detachment [99], consistent with data from fiber studies which 
also show slower rates for detachment of β-myosin [70]. A decrease in the rate of 
detachment would result in an increased time spent for strongly bound myosin 
allowing for increased recruitment of myosin cross-bridges to the thin filament 
which could account for the increased force production observed for β-myosin. 
This demonstrates a role for thick filament regulation via myosin strong binding in 
muscle contraction, and shows that myosin isoform composition may influence 
the contractile properties and energetics of the muscle tissue. 
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1.2.5 Load Dependence 
   A load is a resisting force that is applied to an object. Under physiological 
conditions, cardiac muscle always experiences a load as it contracts. When there 
is no load imposed on a muscle, it will contract at maximal shortening velocity. 
When a load imposed on muscle is equal to the force producing capabilities of 
the muscle, the muscle will generate tension equal to the load but will not 
shorten. This is called isometric contraction because the muscle remains at a 
constant length. Muscle produces no work at either of these two extremes since 
work is the exertion of force over a distance. The ability of the heart to pump 
blood depends on its ability to produce work (i.e. shorten against a load), and 
therefore it is important to understand how load affects the biochemical and 
mechanical processes of muscle contraction. 
  In 1923, Fenn showed that the rate of heat production from a contracting 
muscle decreases as the load increases [31]. This was the first evidence to show 
that load slows the rate of energy release during muscle contraction. This slower 
rate of energy release stems from a decrease in the actomyosin ATPase rate 
[50]. A slowing of the chemical turnover from ATP hydrolysis allows the muscle to 
conserve energy under higher loads. Load can only be transmitted to the myosin 
motor when it is bound to actin, therefore load can only affect the biochemical 
transitions that are associated with a strongly bound state. 
  There is ample evidence that load affects the rate of ADP release from 
myosin. For example, measurement of MgADP accumulation using fluorescent 
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probes demonstrated a significant increase in the steady-state rate of MgADP 
release during fast shortening velocities compared to isometric contractions [49, 
133]. Without any other changes in the ATPase cycle, a slower ADP release rate 
would result in a higher duty cycle for myosin under load. This could serve to 
increase the population of myosin cross-bridges bound to actin at higher loads, 
and thus allow a greater force to be produced by the muscle. 
  It has been proposed the load-sensitive mechanism affecting ADP release 
involves an isomerization (i.e. molecular rearrangement with no change in 
chemical structure) of the myosin molecule in the ADP bound state. The 
isomerization is the above described continuation of the lever arm swing which 
results in the opening of the nucleotide-binding pocket. This would shift myosin to 
a conformation that facilitates nucleotide exchange from the binding pocket. 
Loading the myosin would cause an inhibition of the lever arm swing in the ADP 
bound state, thus preventing the isomerization and inhibiting ADP release [36, 
95]. Thus load can alter the mechanical and chemical properties of myosin. In the 
experiments presented in chapter 3, we use a non-motor actin-binding protein to 
introduce a load in the motility assay in order to provide a more physiologically 
relevant measure mimicking native actomyosin mechanochemistry. 
 
1.3 Heart Physiology 
  The heart works as a pump to circulate blood throughout the 
cardiovascular system, a vast network of blood vessels that form a closed loop to 
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carry blood from the heart to all the peripheral tissues and organs of the body 
and back to the heart. Blood is the aqueous transportation medium of our body 
that delivers oxygen, hormones, antibodies, cellular building blocks for growth 
and repair, and various nutrients to bodily tissues and removes carbon dioxide 
and metabolic waste products while distributing heat throughout our body, all 
serving to maintain homeostasis. Arteries carry oxygen and nutrient rich blood 
from the heart to all of our cells and veins carry deoxygenated blood back to the 
heart. The largest diameter blood vessels connect directly to the heart and then 
repeatedly branch into smaller vessels until they reach all of the cells in our body. 
The arterial and venous systems are connected by capillaries, the smallest of the 
blood vessels which are a short distance from cells and allow for the efficient 
exchange of nutrients and waste products via diffusion.  The heart is responsible 
for maintaining the circulatory needs of the body by continually pumping blood 
from the venous network to the arterial network (Figure 1.11). The effects of the 
RLC mutations and phosphorylation on muscle contraction ultimately affect the 
pump function of the heart. In the remainder of this chapter I will describe general 
structure-function aspects of the heart (section 1.3.1) and how these aspects are 
affected by RLC phosphorylation (section 1.3.2) and cardiomyopathy-linked 
mutations (section 1.3.3).  
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1.3.1 Gross Anatomy and Function  
  The heart is composed of four chambers, the top two chambers are atria 
which collect blood coming into the heart, and the bottom two chambers are 
ventricles which pump blood out of the heart. The heart functions as two pumps 
in series, the right atrium and right ventricle forming one pump and the left atrium 
and left ventricle forming the second pump (Figure 1.11). Each pump contains an 
atrioventricular (AV) valve which allows the one-way flow of blood from the atrium 
to the ventricle. The right side of the heart is a low pressure pump. It pumps 
deoxygenated blood from the vena cava through the pulmonary arteries to the 
lungs. The left side of the heart is a high pressure pump. Oxygenated blood from 
the lungs flows through the 
pulmonary veins into the left 
atrium. The left ventricle is 
responsible for pumping 
blood into the aorta and 
through the entire systemic 
circulation back to the right 
side of the heart.  
  The heartbeat occurs 
in two phases, diastole and 
systole. During diastole the 
muscle relaxes and the 
 
Figure 1.11: Blood Flow through the Heart 
The right side of the heart pumps blood through the 
pulmonary circuit . The left side of the heart pumps 
blood through the systemic circuit. Adapted from 
http://www.texasheart.org/HIC/Anatomy/Anatomy.cfm
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chambers fill with blood. During systole the muscle contracts and blood is 
ejected. The diastolic and systolic periods are synchronized between the right 
and left sides of the heart, and in order to ensure proper filling of all four 
chambers atrial contraction precedes ventricular contraction. Cardiac contraction 
is initiated by depolarization of specialized cardiac cells that exhibit 
autorhythmicity, the ability to fire action potentials on their own. These cells are 
called pacemaker cells and form a conduction system in the heart through which 
electrical impulses spread rapidly to initiate a timed contraction of the 
myocardium. The heart rate (beats per minute) is determined by the pacemaker 
cells with the fastest firing rate. Cardiac output is the volume of blood pumped by 
the heart per minute. It is the product of heart rate and the stroke volume, the 
amount of blood pumped per heartbeat. Cardiac output must be maintained at a 
sufficient rate to deliver adequate and continuous supply of oxygen and other 
nutrients to the body. As bodily demand varies, such as during exercise, so must 
cardiac output. 
  Ventricular contractility during one heartbeat cycle can be visualized by 
plotting ventricular pressure versus ventricular volume (Figure 1.12). The 
ventricular cardiac cycle is divided into four phases: diastolic filling, systolic 
isovolumetric contraction, systolic ejection, diastolic isovolumetric relaxation.  
During diastole the AV valve opens and blood from the atrium fills the ventricle. 
Systole begins just prior to AV valve closure. At this point the ventricle contracts 
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isovolumetrically because 
blood cannot be ejected 
from the left ventricle until 
the ventricular pressure 
reaches or exceeds the 
pressure in the aorta. When 
left ventricular pressure 
reaches aortic pressure, 
the aortic valve opens, and 
ejection begins. The end of 
systole is marked by 
closure of the aortic valve. 
At this point the ventricle 
will relax isovolumetrically 
until the AV valve opens 
once again. The stroke 
volume of contraction is 
represented by the 
difference between end 
diastolic volume and end 
systolic volume. The work 
 
Figure 1.12: Ventricular Pressure During Heartbeat 
The P-V loop demonstrates the four phases of the 
heartbeat. The area within the loop represents work 
done by the left ventricular muscle. 
Aortic pressure represents the afterload that the left 
ventricle must overcome to eject blood. Valve openings
and closings are depicted with the same symbols as in 
the top panel. The echocardiogram (ECG) measures 
electric current in the heart and shows that 
depolarization coincides with the onset of systolic 
contraction. Adapted from [45]. 
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capacity of the ventricle is represented by the area within the P-V loop. 
  Work capacity is essentially the amount of the energy that the ventricle 
can expend during one heartbeat cycle. One major factor that determines the 
energy requirement for blood ejection is the afterload. Afterload is the force that 
opposes ventricular contraction, and is represented by aortic pressure for the left 
ventricle. The higher the afterload, or aortic pressure, the more energy the 
ventricle must expend to build the pressure needed to open the aortic valve. This 
leaves less energy for the next phase of contraction where muscle shortens to 
eject blood. The work capacity of the muscle is an important determinant of 
stroke volume and relies on how much force the muscle can produce. The P-V 
loop shows the work capacity for one heartbeat cycle, however the heart must be 
able to beat repetitively. Therefore, not only does the ventricle have to perform 
sufficient work, but it must do so at a sufficient rate. Cardiac power output is the 
rate at which the ventricle can perform work, and it represents the heart’s ability 
to efficiently pump blood [4, 80, 85, 128].  
  The same amount of blood flows through the left and right sides of the 
heart but the left ventricle has to work much harder to pump blood because it 
experiences a higher afterload. Blood entering the aorta travels through the 
entire systemic circulation back to the right side of the heart, whereas blood in 
the pulmonary circuit travels to the lungs, a low resistance circuit, before 
returning to the left side of the heart. The pressure in the aorta is five times 
greater than the pressure in the pulmonary artery to accommodate the greater 
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resistance in the systemic circulation. The two genetic mutations of the RLC 
studied in this work lead to a remodeling of the left ventricle which disrupts its 
ability to function properly. 
  The left ventricle is anatomically suited to pump against the higher 
pressures of the systemic circuit. The left ventricle has a conical shape with its 
base at the interface with the atrial chamber and aortic valve. The myocardium is 
an entangled web of muscle fibers and the gross nature of the tissue structure is 
still debated. The ventricular tissue is often discussed in terms of layers 
comprising the wall assigned as epicardial (outer), middle, and endocardial 
(inner). It is important to note that these are not distinct or separated layers within 
the ventricular wall as fibers interconnect transmurally to form a continuum.  
However, it is clear that fiber orientation changes transmurally through the wall. 
The endocardial and epicardial fibers are arranged in opposing oblique 
orientations, while those in the middle are to those found to be circumferentially 
aligned (Figure 1.13). The contrasting orientation of fibers allows the ventricle to 
generate torsion as it contracts to “wring out” blood [7, 46]. During contraction the 
longitudinal axis of the left ventricle varies only slightly in length as the chamber 
circumference significantly decreases. Ventricular torsion places different 
contractile requirements on fibers found in different regions of the wall, such as 
more forceful contractions for epicardial fibers [30]. In the following section I will 
discuss mechanisms of RLC phosphorylation that modulate cardiac contraction, 
including a potential role in maintaining ventricular torsion.  
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  The left ventricular myocardium must work against the afterload imposed 
on the heart by aortic blood pressure and peripheral resistance. Ejection is 
further constrained to the duration of systole for each heartbeat. Therefore the 
shortening velocity of contraction under load will determine the volume of blood 
ejected from the ventricle per heartbeat. Power can be calculated as the product 
of force and velocity. Subtle changes to the force-velocity relationship of muscle 
contraction will have profound effects on cardiac power output, and subsequently 
heart function. In chapter 3 we introduce exogenous loads to the in vitro motility 
assay to mimic a more physiological, loaded experimental system and calculate 
the effects of the mutations and phosphorylation on actomyosin power. 
 
 
1.3.2 Modulation of Cardiac Contraction via RLC Phosphorylation 
Cellular Effects 
 
Figure 1.13: Anatomy of the Left Ventricle 
The orientation of muscle fibers in the wall of the left ventricle changes with transmural 
position. Adapted from [7, 46].  
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  The pump function of the heart must be finely tuned to maintain sufficient 
cardiac output over a wide range of physiological conditions. The dominant 
regulatory control of cardiac contraction is the binding of calcium to the thin 
filament which exposes binding sites on actin and permits myosin cross-bridges 
to engage the thin filament. As calcium levels rise during an activating transient, 
so does the rate of ATP hydrolysis from the actomyosin biochemical cycle along 
with tension generation in muscle fibers. The calcium sensitivity of muscle to 
ATPase or force is commonly measured by determining the amount of calcium 
necessary to reach half maximal activation; a greater sensitivity to calcium 
means that less calcium is required to reach half maximal activation. Myosin 
strong binding to actin at submaximal calcium is a mechanism that modulates the 
activation of cardiac contraction (see Figure 1.7). RLC phosphorylation, while 
regulatory for invertebrate and smooth muscle, has a modulatory role in cardiac 
muscle contraction, subtly modifying and fine tuning the rates of cross-bridge 
attachment to and detachment from actin [120]. 
  Various in vitro fiber studies have shown that phosphorylation of the RLC 
increases the calcium sensitivity of force for skeletal fibers [81, 104] and cardiac 
fibers, including those from mouse, rat, rabbit, pig and human [22, 86, 87, 115, 
130, 135]. This leftward shift of the tension-pCa relationship acts to increase the 
duration of muscle contraction due to an early onset of activation and delayed 
onset of relaxation. An increase in the calcium sensitivity of a muscle cell, as 
seen with RLC phosphorylation, would most likely arise from an increase in 
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myosin strong binding at submaximal calcium as opposed to increased calcium 
binding to troponin to activate the thin filament. Myosin is more likely to occupy a 
strong binding state when the spacing between myofilaments is decreased [74]. 
In fact, it is well established that decreased interfilament lattice spacing of muscle 
fibers increases the calcium sensitivity of force [77, 153]. An in depth study by 
Colson et al. [23] directly confirmed the notion that RLC phosphorylation 
decreases lattice spacing to increase Ca2+ sensitivity using a combination of X-
ray diffraction and mechanical fiber techniques to study murine trabeculae. 
  Colson and colleagues observed a second structural alteration induced by 
RLC phosphorylation in the mouse fibers. The distribution of mass from myosin 
cross-bridges showed a net movement away from the thick filament and closer to 
the thin filament, as determined from 1,0 and 1,1 equatorial reflections in resting 
fibers. This phenomenon has been widely studied in skeletal muscle, and 
demonstrated using electron microscopy [69] and fiber diffraction techniques 
[98], however the study mentioned above was first to demonstrate the structural 
change in cardiac muscle. It has been proposed that phosphorylation induces a 
charge repulsion of myosin heads away from the thick filament, and this is 
supported by charge replacement studies of the RLC [137]. Importantly, the net 
transfer of cross-bridge mass is a separate effect from the decreased lattice 
spacing of myofilaments as determined from x-ray fiber diffraction experiments. 
Phosphorylation of MyBP-C, another thick filament associated protein, but not 
RLC, also resulted in a net transfer of cross-bridges away from the thick filament 
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with no corresponding decrease in lattice spacing, and subsequently there was 
no change in the calcium sensitivity for these fibers [23]. 
  The disposition of myosin heads off the thick filament backbone manifests 
as an increase in the rate of force development of the fiber, which is seen for 
muscle fibers containing phosphorylated RLC (and also phosphorylated MyBP-C) 
[23]. Mechanical studies on skeletal and cardiac fibers have demonstrated 
increased rates of force development upon phosphorylation of the RLC [23, 88, 
130, 136]. By lifting the myosin cross-bridges off the thick filament backbone, 
RLC phosphorylation orients myosin heads in a more optimal position to bind the 
thin filament which presumably leads to an increase in the rate of cross-bridge 
attachment. Increasing the rate of attachment to actin will increase the number of 
myosins occupying a strongly bound state through two mechanisms: (1) it 
decreases the time spent in a detached state for the population of 
phosphorylated myosin, and (2) it increases the rate of exposure of actin-binding 
sites for neighboring myosins. 
  It is evident that phosphorylation of the RLC has the ability to markedly 
alter cardiac contraction. RLC phosphorylation alters the sarcomeric lattice and 
thick filament structure to fine tune activation and increase recruitment of myosin 
motors via changes in strong binding kinetics. Each effect contributes to the 
pump function of the heart. By increasing the calcium sensitivity to force, it 
follows that RLC phosphorylation allows the muscle more time to contract during 
systole by initiating contraction at an earlier stage of the activating calcium 
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transient. Increasing the rate of force development allows the muscle to develop 
pressure faster. During the isovolumetric contraction phase of systole, the faster 
left ventricular pressure reaches the afterload, the more time it can spend 
ejecting blood during systole. 
Global Tissue Effects  
  RLC phosphorylation levels in the heart are determined by the relative 
activity of kinases and phosphatases. A cardiac specific myosin light chain 
kinase (cMLCK) has been identified [17]. It is exclusively expressed in cardiac 
tissue and the myosin RLC is its only known substrate. Changes in the 
expression level of cMLCK result in changes to RLC phosphorylation levels; 
however, this is not seen for other kinases in the heart. RLC phosphorylation is 
maintained at a steady state level of approximately 45% due to the competitive 
actions of cMLCK and myosin light chain phosphatase holoenzyme [18]. The 
phosphatase is known to have a multiple substrates in cardiac tissue. However, 
when myosin phosphatase target subunit 2 (MYPT2) binds to the phosphatase, 
the holoenzyme becomes specific for the RLC [83, 97]. The specificity of control 
exerted over RLC phosphorylation and its sustained presence suggests it is an 
important contributor to basal cardiac function. 
  While RLC phosphorylation levels in the human heart are maintained at 
about 45%, the pattern of RLC phosphorylation is not uniform in the heart. Given 
that RLC phosphorylation is constitutively maintained in a specific pattern, it is 
likely to infer regional influences over the heart. RLC phosphorylation is present 
  
33 
at higher levels in the epicardium and near the apex of the heart in humans, 
rabbits and rodents [25, 48, 123, 154]. It was also found in higher levels in the 
specialized Purkinje fibers of the mouse heart [154]. Evidence suggests that this 
gradient is functionally significant in maintaining left ventricular torsion and 
untwisting necessary for proper left ventricular ejection and relaxation [26]. 
Muscle fibers that are required to perform at enhanced levels to create torsion 
correlate with areas of increased RLC phosphorylation in the heart [25]. Gene 
targeted knock in mice bearing non-phosphorylatable RLC showed a loss of left 
ventricular torsion and untwisting compared to WT mice. Computational models 
that mimicked this effect also predicted that uniform phosphorylation of the 
ventricle could not maintain torsion to the same degree as measured in WT mice 
[123]. These findings suggest that basal heart function is sustained through 
regional mechanical differences caused by RLC phosphorylation.  
  Thin filament regulation is extremely cooperative and acts as an on/off 
switch for muscle contraction on a beat to beat basis. However the dynamic 
environment experienced by the heart and the demand for optimal performance 
requires more than a simple on/off mechanism. The heart is constantly adapting 
to the circulatory needs of the body as it experiences a broad range of conditions 
including rest, exercise, fight or flight, injury, etc. Thick filament regulation via 
RLC phosphorylation represents a possible mechanism to finely tune heart 
function as it experiences varying conditions over longer time scales. 
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  The levels of phosphorylation can be regulated to adapt to the demands 
placed on the heart under varying conditions. For example, isolated rat hearts 
subjected to differing levels of left ventricular passive stretch were shown to have 
phosphorylation levels in the endocardium that were significantly reduced 
compared to those in the epicardium under diastolic pressure of 15 mmHg. In 
contrast, phosphorylation levels were equal between endocardial and epicardial 
tissue under a diastolic pressure of 0 mmHg [48]. Muscle hypertrophy is an 
enlargement of the muscle tissue due to an increase in the size of the component 
cells. Exercise conditioning in mice results in physiological hypertrophy, however 
increased RLC phosphorylation in transgenic mice resulted in an attenuation of 
physiological hypertrophy following treadmill exercise [52]. In addition, the 
expression of cMLCK was upregulated in mice that underwent swimming 
exercise, which lead to an increase in RLC phosphorylation levels from 33 to 
39% [154].  These studies support the idea that RLC phosphorylation levels are 
dynamic and regulated in response to the demands placed on the heart. 
  The level and pattern of RLC phosphorylation has proved to be critical to 
the basal function and adaptive properties of the heart. It is therefore not 
surprising that non-physiological and pathological changes resulting in reduced 
levels of RLC phosphorylation are correlated with poor cardiac performance in 
vivo. Multiple studies of transgenic mice expressing non-phosphorylatable RLC 
exhibited myocyte structure abnormalities, cardiac remodeling, and left 
ventricular dysfunction including decreased pressure, stroke volume and power 
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output ultimately leading to heart failure [115, 118, 123]. Similar studies in which 
cMLCK expression was ablated lead to decreased or complete loss of RLC 
phosphorylation in transgenic mice which resulted in an inability to adapt to 
external stresses, hypertrophy and severe heart failure [29, 154]. Likewise, 
decreased RLC phosphorylation resulting from increased expression of the 
myosin phosphatase holoenzyme lead to left ventricular remodeling and impaired 
function [83]. Consistent with findings in the murine animal model, genetic 
screening of 490 patients with cardiac hypertrophy revealed a mother and son 
bearing mutations in MLCK [25].  RLC phosphorylation is critical to cardiac 
function, and alterations in the levels of RLC phosphorylation have been linked to 
heart failure in human patients [142].  
 
1.3.3 Familial Hypertrophic Cardiomyopathy 
  Familial hypertrophic cardiomyopathy (FHC) is the most common type of 
genetic heart disease in United States [35]. It affects about 1 in 500 people and is 
a leading cause of sudden cardiac death in adolescents. The condition is 
characterized by asymmetric ventricular hypertrophy, usually in the left ventricle 
or ventricular septum, and is often accompanied by myocyte disarray and fibrosis 
(Figure 1.14). Decreased chamber size and increased wall stiffness are 
symptoms of hypertrophy which commonly lead to diastolic relaxation and filling 
abnormalities [21]. FHC is caused by autosomal dominant mutations in genes 
that encode sarcomeric proteins. There are hundreds of known mutations in at 
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least 11 genes that are expressed in 
the heart [121]. However, it remains 
unclear how the disease manifests, and 
the clinical presentation, prognosis and 
treatment for FHC are extremely 
heterogeneous [150].  
  Many patients that exhibit 
hypertrophy have an otherwise normal 
functioning heart and remain symptom 
free, while for others the disease may 
manifest in diastolic dysfunction, 
progressive heart failure, atrial 
fibrillation, or sudden cardiac death 
(SCD). Other symptoms may include 
chest pain, dizziness, shortness of breath, and lethargy [21]. There is no cure for 
FHC; treatment options are limited and focus exclusively on treating the most 
severe symptoms rather than the cause of the disease [76]. This is in part due to 
the fact that it is hard to detect FHC before cardiac remodeling occurs, at which 
point treatment relies on management of the disease and assessment of the risk 
for SCD. For individuals who are at high risk of SCD, a defibrillator may be 
surgically implanted to reduce their risk of SCD [58]; however, often times SCD is 
the first obvious manifestation of the disease. Early detection of FHC is 
Figure 1.14: FHC Pathology 
A heart from a patient with FHC exhibits 
severe asymmetric left ventricular 
hypertrophy and reduced chamber size. 
Histological analysis shows significant 
myofiber disarray and interstitial fibrosis 
compared to normal heart tissue [20].  
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necessary in order to invest in preventative therapies and intervene at a stage 
when the disease can be attenuated. For this reason there has been a major 
push in recent years to develop more robust genetic screening technologies and 
increase their availability [13].  
  Early diagnosis is only one part of the battle in developing successful 
therapeutic measures. Not only does the clinical presentation of FHC vary widely, 
but the pathophysiology is unique to the specific disease-causing mutation [20, 
58]. Development of therapeutic strategies requires knowledge of the molecular 
defects posed by the causal mutation as well as how these underlying defects 
trigger hypertrophy. This is the motivation behind much of the basic research that 
is carried out on FHC-linked mutations today, including studies performed here 
aimed at characterizing the molecular phenotype of mutations in the myosin RLC 
and potential rescue mechanisms (section 3.5). Hopefully our work can 
potentially pave the way for treatments that correct dysfunction before significant 
hypertrophic remodeling.  
  Familial hypertrophic cardiomyopathy is a disease of the sarcomere, most 
likely stemming from impaired muscle contraction, structure and/or energetic 
consumption. Mutations can arise in almost any component or region of the 
sarcomere, exerting a wide range of effects at the molecular level, yet leading to 
a seemingly shared phenotype. This suggests that mutations with varying defects 
may share common functional consequences that trigger hypertrophy. For 
example, a mutation that reduces force production might trigger compensatory 
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hypertrophy in order to restore force by building more muscle. Likewise, a 
mutation that decreases the calcium sensitivity of activation and results in less 
cross-bridge recruitment, could also reduce force production, and in turn lead to 
compensatory hypertrophy. Hypertrophy may also be a direct result of the 
mutational defect. For example, a mutation that impairs the structural integrity of 
the sarcomere may lead to a direct remodeling of cardiac fibers, or a mutation 
that increases the calcium sensitivity of activation may lead to improper diastolic 
relaxation, and could result in hypertrophy from sustained activation. Since 
multiple contractile alterations ultimately result in the same end point of 
hypertrophy, one must understand the pathology of any given mutation so that 
treatments can be tailored for each individual.  
  
 
Cardiomyopathy-linked Mutations of the RLC 
  There are currently 13 documented FHC mutations in the MYL2 gene that 
encodes the ventricular myosin regulatory light chain: A13T, F18L, M20L, E22K, 
N47K, R58Q, P95A, L103E, E134A, I158L, G162R, D166A, D166V [5] and one 
linked to dilated cardiomyopathy, D94A [53]. I studied two of these mutations, 
N47K and R58Q, to discern their effect on myosin function at the molecular level. 
While both mutations are located in the RLC N-terminus in close proximity to 
each other, each displays a drastically different disease phenotype. The N47K 
mutation is associated with mid-ventricular and papillary muscle hypertrophy 
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resulting in diastolic filling abnormalties. The onset of hypertrophy occurred late 
in life when the affected patient was in their late 50s, and rapidly progressed in 
the following the years [6]. The R58Q mutation is associated with a classic FHC 
phenotype of left ventricular hypertrophy, and an early onset occurring during 
childhood. The R58Q mutation is associated with multiple cases of sudden 
cardiac death [34]. 
  Based on the crystal structure of skeletal RLC (Figure 1.9), N47 and R58 
are located near the phosphorylation site and cation site of the RLC, with N47 
forming part of the cation binding site [106]. Bacterially expressed human 
ventricular RLC (hvRLC) bearing either mutation abolished calcium binding to the 
isolated RLC in solution [138, 139]. The ability to bind calcium was restored to 
R58Q RLC upon phosphorylation of S15, and was accompanied by an increase 
in helical content [139]. When bacterially expressed N47K mutant RLCs were 
exchanged onto porcine cardiac fibers to test their sensitivity to calcium 
activation, the fibers displayed a significantly increased calcium sensitivity to the 
myofibrillar ATPase, while R58Q fibers displayed a significantly increased 
calcium sensitivity to force [138].  
  To gain an understanding of how RLC modifications affect myosin 
contractility, I studied cardiac β-myosin bearing WT and mutant hvRLC in the 
dephosphorylated and phosphorylated states using in vitro motility assays. In 
vitro motility assays retain the strengths of solution biochemistry experiments 
while simultaneously permitting the measurement of actomyosin contractility. 
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Unlike fiber studies which characterize bulk properties of muscle ensembles, the 
motility assay allows for the characterization of individual protein components 
within the system. Thus, it provides the advantage of distinguishing molecular 
based changes to myosin contractility directly resulting from RLC modifications. 
  Previous studies have shown that N47K and R58Q mutations disrupt 
myosin’s strain sensitivity, stemming from a more compliant lever arm 
[Greenberg Thesis]. In contrast, RLC phosphorylation was shown to impart 
stiffness to the lever arm in skeletal muscle studies [Greenberg, 2009].  We 
hypothesized that phosphorylation of the FHC-RLC may mitigate distinct 
mutation-induced structural and functional abnormalities of the myosin motor. 
  To study the disease-linked mutations in the specific protein isoform in 
which they are found, bacterially expressed human ventricular RLCs were 
utilized in our experiments, however, because heart tissue samples from healthy 
adults are extremely difficult to obtain and are not readily available, myosin heavy 
chains were isolated from an animal model. The human ventricular myocardium 
is predominantly comprised of the β-MHC isoform, expressing a 9:1 ratio of β-
MHC to α-MHC, and undergoes a shift to 100% β-MHC expression during heart 
failure [82]. The porcine cardiac β-MHC is 98% identical to human β-MHC, a 
difference of 45 out of 1935 amino acids, 26 of which are conserved 
substitutions.  It is important to study pathological and physiological phenomenon 
in the context of which they are occur, and β-MHC from porcine hearts provides a 
relevant framework for our studies.  
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  In the work presented here, in vitro motility assays were utilized to 
investigate the effects of RLC phosphorylation on the FHC-RLC mutant 
phenotype in the presence of an α-actinin frictional load. The methodology, 
results and a discussion of my findings are presented in the following chapters of 
this thesis. 
  
  
42 
CHAPTER 2 – METHODS AND MATERIALS 
 
2.1 Purification of Proteins 
2.1.1 Porcine Cardiac Myosin 
  The left ventricle was removed from porcine hearts, and minced while 
chilled on ice. The minced tissue was ground, and 50-100 g of tissue was 
homogenized in 100 to 200 ml of Extraction Buffer (0.3 M KCl, 15 mM potassium 
phosphate, 20 mM EDTA, 5 mM MgCl2, 5 mM DTT, 3.3 mM ATP, pH 6.7). The 
homogenate was diluted 4-fold with cold (4o C) distilled deionized water (ddH20) 
and filtered through cheesecloth. The solution was then diluted 10-fold with cold 
ddH20 and allowed to precipitate for 4 hours at 4o C.  The precipitate was 
collected by centrifugation (10,000 x g for 20 minutes) and resuspended in 1 M 
KCl, 60 mM potassium phosphate, 20 mM EDTA, 5 mM DTT, pH 6.7. The 
solution was dialyzed overnight against 0.6 M KCl, 25 mM potassium phosphate, 
5 mM DTT, pH 6.7 at 4o C.  An equal volume of cold ddH20 was then added to 
the solution, stirred for 30 min at 4o C, followed by centrifugation at 41,000 x g for 
1 hour to remove filamentous actin. Following centrifugation there was a distinct 
actin-containing pellet, a clear middle-layer supernatant containing myosin, and a 
cloudy top-layer containing fat. The middle layer was removed using a transfer 
pipette; the pellet and top-layer were discarded. The supernatant was diluted 10-
fold with cold H20 and allowed to precipitate for 4 hours at 4o C.  The precipitate 
was collected by centrifugation (10,000 x g for 20 min) and resuspended in 3 M 
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KCl, 50 mM potassium phosphate, 5 mM DTT, pH 6.7, then dialyzed overnight 
against 0.6 M KCl, 50 mM potassium phosphate, 5 mM DTT, pH 7.0 at 4o C. A 5 
mL volume of this buffer was saved for later use in determining protein 
concentration. The protein solution was clarified by centrifugation at 41,000 x g 
for 1 hour, and the supernatant was collected. Protein concentration was 
determined by measurement of solution absorbance at 280 nm (and reference 
wavelength at 320 nm) for three dilutions (1:25, 1:50, 1:100). An equal volume of 
cold glycerol (4o C) was added to the remaining protein solution and the resulting 
PC myosin was stored in 50% glycerol for up to three months at -20o C, until 
needed for experiments. 
 
2.1.2 Regulatory Light Chains 
  Bacterially expressed human ventricular regulatory light chains (hvRLC) 
were prepared by our collaborators (D. Szczesna-Cordary Lab, University of 
Miami – Miller School of Medicine) as previously described [139]. Briefly, the 
cDNA (GenBank™ Accession No. AF020768) for wild-type (WT) and mutant 
(N47K and R58Q) hvRLCs were constructed with an NcoI site at the N-terminal 
ATG and a BamHI site following the stop codon to facilitate ligation into the NcoI–
BamHI cloning site of the pET-3d (Novagen) plasmid vector. The vector was 
transformed into DH5-α cloning host bacteria for amplification. The vectors were 
transformed into BL21 expression host cells and all proteins were expressed in 
large (16 liter) cultures. Expressed proteins were purified using a S-Sepharose 
  
44 
column followed by a Q-Sepharose column, both equilibrated with 2 M urea, 25 
mM Tris–HCl, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM DTT, 0.001% 
NaN3, pH 7.5. The proteins were eluted with a salt gradient of 0 to 450 mM NaCl. 
The final purity of the proteins was evaluated using 15% SDS–PAGE. The 
hvRLCs were dialyzed against 2 M urea and stored at -80° C. 
 
2.1.3 Myosin Light Chain Kinase 
  Smooth muscle myosin light chain kinase (MLCK) was isolated from 
chicken gizzards based on the protocol of Ngai et al. [93].  For the extraction 
procedure all steps were carried out in the cold room, and buffers were kept at 
4ºC. Chicken gizzards were thawed on ice and minced after connective tissue 
removal. The muscle mince (50g) was homogenized for three five second pulses 
in 200 mL wash buffer containing 20 mM Tris-HCl, 40 mM NaCl, 1 mM MgCl2, 1 
mM EGTA, 1 mM DTT, pH 7.5 supplemented with 0.05% Triton-X-100, then 
centrifuged at 17,000 g for 15 min at 4o C. The pellet was homogenized in wash 
buffer and collected by centrifugation (17,000 x g for 15 min at 4oC). This step 
was repeated. The blender was rinsed with ddH2O between each centrifugation 
cycle. The pellet was resuspended in 200 mL extraction buffer containing 40 mM 
Tris-HCl, 60 mM NaCl, 25 mM MgCl2, 1 mM EGTA, 1 mM DTT, pH 7.5 and 
centrifuged at 17,000 x g for 15 min at 4oC.  The supernatant was filtered through 
glass wool and clarified via centrifugation at 250,000g for 45 min at 4o C. The 
supernatant was collected and filtered through a low protein binding syringe filter.  
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  DEAE resin was washed three times in DEAE loading buffer (40 mM Tris-
HCl, 20 mM NaCl, 25 mM MgCl2, 1 mM DTT, 1 mM EGTA, pH 7.5). A third of the 
resin (~20 mL) was set aside for batch binding. The rest of the resin was packed 
into a DEAE Sepharose column, and washed with DEAE elution buffer (40 mM 
Tris-HCl, 1 M NaCl, 25 mM MgCl2, 1 mM DTT, 1 mM EGTA, pH 7.5), and then 
re-equilibrated in DEAE loading buffer. The resin set aside for batch binding was 
allowed to settle for 10 minutes and excess buffer was removed, resulting in a 
concentrated slurry. The clarified protein solution was added to the resin slurry 
and mixed on an orbital shaker overnight at 4oC.  
  Batch bound resin was loaded onto the DEAE sepharose column. The 
column was equilibrated by addition of DEAE loading buffer until absorbance 
readings at 280 nm of flow through fractions reached a steady state baseline.   A 
linear salt gradient was accomplished by mixing equal volumes of DEAE loading 
and elution buffers in a gradient mixer that was gravity fed into the column. The 
enzyme was eluted with a gradient from 20 to 300 mM NaCl over 3 column 
volumes. Protein fractions containing the kinase were determined by SDS-PAGE, 
and then pooled. The pooled fractions were dialyzed overnight against Cibracon 
loading buffer (20 mM K2HPO4, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 0.02% 
NaN3, pH 8.0).  Following dialysis the kinase enriched fractions were centrifuged 
at 300,000 x g for 10 min at 4o C. The supernatant was loaded onto an Affi-Gel 
Blue (Bio-Rad Laboratories, Inc., Hercules, CA, cat #153-7301) column 
equilibrated in Cibracon loading buffer. The kinase was eluted with a gradient 
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from 0 to 1.5 M NaCl in the same buffer over 10 column volumes. Protein 
fractions containing the kinase were determined by SDS-PAGE, and then pooled. 
Pooled fractions were dialyzed overnight against a buffer containing 25 mM 
MOPS, 50 mM NaCl, pH7.5. Enzyme concentration was determined using a 
Bradford Assay (Bio-Rad Laboratories, Inc., Hercules, CA). MLCK was mixed 1:1 
with glycerol and stored for up to one year at -20o C until needed for experiments.  
 
2.2 Preparation of Proteins 
2.2.1 RLC Phosphorylation 
  Human recombinant RLC (WT, N47K or R58Q) was dialyzed against 25 
mM MOPS, 25 mM NaCl, 10 mM MgCl2, 0.2 mM PMSF, pH 7.3, 5 mM DTT at 
4ºC. Calmodulin (CaM) purchased from AG Scientific, Inc. (San Diego, CA, cat 
#C-1431) was pre-incubated with MLCK in a buffer containing 25 mM MOPS, 25 
mM NaCl, 10 mM MgCl2, 0.2 mM CaCl2, pH 7.3, 40% glycerol, 5 mM DTT. Equal 
volumes of RLC and MLCK/CaM solutions were mixed together at room 
temperature, and ATP was added at final concentration of 5 mM to initiate the 
phosphorylation reaction. The stock ATP solution was adjusted to pH 6 prior to 
being added to the reaction in order to prevent significant acidification and 
subsequent precipitation of proteins in the reaction. RLCs at a concentration of 
~100 μM were phosphorylated with 0.25 μM MLCK and 1 μM CaM in a buffer 
containing 25 mM MOPS, 25 mM NaCl, 10 mM MgCl2, 0.1 mM CaCl2, 0.1 mM 
PMSF, pH7.3, 20% glycerol, 5 mM DTT, 5 mM ATP.  The reaction was incubated 
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at room temperature for 1 hour and then placed on ice. Mock reactions were 
performed alongside phosphorylation reactions for experiments using 
dephosphorylated hvRLCs. In the mock reaction, the volume of MLCK was 
replaced by an equal volume of buffer solution.  To determine the extent of RLC 
phosphorylation, RLCs were dissolved in 8 M urea gel sample buffer and run on 
a 10% polyacrylamide gel containing 8 M urea (see section 2.3.1). 
Phosphorylation reactions and mock reactions remained on ice for 1 to 3 hours 
until the RLCs could be reconstituted on RLC-depleted porcine cardiac (PC) 
myosin. 
  Phosphorylation of native RLC bound to PC myosin was carried out as 
described above for isolated recombinant hvRLCs with the following 
modifications: PC myosin was diluted in 10 volumes of cold ddH20 and 10 mM 
DTT, placed on ice for 1 hour and allowed to precipitate. PC myosin was 
collected by centrifugation at 10,000g for 25 min in a tabletop centrifuge 
(Microfuge® 18, Beckman Coulter, Inc., Pasadena, CA), and resuspended in a 
buffer containing 25 mM MOPS, 300 mM NaCl, 10 mM MgCl2, 0.2 mM PMSF, pH 
7.3, 5 mM DTT. The rest of the procedure was carried out as described above 
except that the reaction was performed at 160 mM NaCl, and in the presence of 
4 μM PC myosin in place of isolated RLCs. Following incubation at room 
temperature for 1 hour, the myosin was precipitated in 10 volumes of cold ddH20 
and 10 mM DTT for 1 hour and collected by centrifugation (10,000 x g for 25 
min). Phosphorylated PC myosin was resuspended in myosin buffer (0.3 M KCl, 
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25 mM BES, 4 mM MgCl2, 1 mM EGTA, pH 7.4, 1 mM DTT), mixed 1:1 in 
glycerol and stored for up to one month at -20º C until needed for experiments.  
 
2.2.2 RLC Depletion and Exchange 
  PC myosin was depleted of its endogenous RLC and reconstitution of 
RLC-depleted myosin was accomplished with bacterially expressed hvRLCs. PC 
myosin (2 mg/mL) was treated with 0.8% Triton X-100 and 15 mM CDTA, in a 
buffer containing 0.5 M KCl, 10 mM potassium phosphate, pH 8.5, for 15 minutes 
at room temperature with slow stirring. Myosin in solution was precipitated with 
10 volumes of cold ddH20 containing 10 mM DTT and collected by centrifugation 
(10,000g for 25 min). Myosin depleted of endogenous RLC was then 
resuspended in a buffer composed of 0.4 M KCl, 50 mM MOPS, pH 7, 2 mM 
MgCl2, and 1 mM DTT and mixed in a 1:3 molar ratio (depleted myosin: RLC) 
with recombinant hvRLC (WT, N47K, or R58Q) and incubated at 4o C for 2 hours 
with slow stirring. RLC-reconstituted myosin was dialyzed in 10 mM MOPS, pH 7, 
5 mM DTT at 4º C and collected by centrifugation (10,000 x g for 25 min). Myosin 
pellets were resuspended in myosin buffer, then mixed 1:1 with glycerol and 
stored at −20°C until needed for experiments. PC myosin, RLC depleted myosin 
and RLC exchanged myosins were analyzed for levels of RLC exchange via 12% 
SDS-PAGE. 
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2.2.3 TRITC Phalloidin Actin 
  Actin filaments were labeled with tetramethylrhodamine isothiocyanate 
(TRITC) and visualized using epifluorescence in in vitro motility assays. The 
TRITC fluorophore emits bright orange light (575 nm peak) when excited with 
yellow-green light (557 nm peak). TRITC conjugated to phalloidin was purchased 
from Invitrogen (Life Technologies, Carlsbad, CA, cat #R415) for the labeling 
reaction. TRITC-phalloidin was resuspended in methanol to a concentration of 
100 μM. Actin was labeled with the TRITC fluorophore by incubating 2 μM 
TRITC-phalloidin with 1 μM unlabeled actin in actin buffer composed of 55 mM 
KCl, 25 mM BES, 5 mM EGTA, 4 mM MgCl2, and 1 mM DTT. The mixture was 
incubated for 2 hours at room temperature, and then 4º C overnight. TRITC-
phalloidin actin was stored at 4º C in actin buffer, and protected from light.  
 
2.3 Polyacrylamide Gel Electrophoresis (PAGE) 
2.3.1 SDS-PAGE 
  Protein samples were frequently analyzed using SDS-PAGE. Gels were 
formed by pouring an acrylamide solution between two gel plates spaced 1 mm 
apart. Protein samples loaded onto the gel are separated by an applied electric 
field which causes the proteins to migrate through the gel based on their 
associated charge. For SDS-PAGE, the gel solution is composed of 375 mM 
Tris-base, pH 8.8, with a specified percentage of Acrylamide/Bis-Acrylamide 
(typically 10-12%). Gels were poured immediately following addition of 0.05% 
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TEMED and 0.05% ammonium persulfate, which initiate polymerization of the 
acrylamide. Protein samples were denatured in 8 M urea, and one part sample 
buffer was added to 4 parts protein sample. Sample buffer was composed of 300 
mM Tris-HCl, pH 6.8, 8 M urea, 500 mg/ml sucrose, 0.05% Bromophenol Blue, 
5% β-mercaptoethanol, and 5% SDS. Protein samples were loaded onto the gel 
and the experiment was carried out in a running buffer composed of 25 mM Tris-
base, 192 mM glycine, pH 8.3, and 0.1% SDS. 
  In SDS-PAGE, denatured proteins are coated in SDS, an anionic 
detergent that applies a negative charge to each protein in proportion to the 
protein’s mass. The mobility of a protein through the gel matrix therefore 
depends on the size of the protein, due to a relatively equal charge-to-mass ratio 
of the protein samples, with smaller proteins migrating at a faster rate towards 
the anode.  
 
2.3.2 Native-PAGE 
  Native-PAGE is one method that can be used to determine the charge 
state of a protein of interest. Using this method, denatured proteins retain their 
native charge, and separation of protein samples in the gel matrix depends on 
the protein’s charge-to-mass ratio. Charge differences between proteins of 
similar size are resolved using native-PAGE, with more negatively charged 
proteins migrating at a faster rate toward the anode and further through the gel 
matrix. Urea-PAGE and glycerol-PAGE are two types of native-PAGE that are 
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used to determine protein phosphorylation states of myosin light chains [103, 
125].  
  For native-PAGE experiments, the same protocol was used as for SDS-
PAGE except no SDS was added to the sample buffer or running buffer. In 
addition the gel solution was supplemented with either 8 M urea or 40% glycerol. 
The only difference between the urea-PAGE and glycerol-PAGE preparation was 
the composition of the gel matrix. The two methods were compared to determine 
which gel medium provided a better resolution of charge separation between 
dephosphorylated and phosphorylated RLC. Differences in the resolution of 
protein separation between urea-PAGE and glycerol-PAGE were negligible 
(Figure 2.1). However the glycerol based gel required an additional 2 hours to 
                
 
Figure 2.1: Comparison of 10% PAGE using Glycerol versus Urea in Gel Medium 
Porcine cardiac myosin that underwent phosphorylation and mock reactions were 
compared using 10% PAGE containing either 40% glycerol (left) or 8 M urea (right). The 
resolution of the protein band shift due to phosphorylation was not considerably different 
between the two methods. 
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polymerize compared to the urea-based gel, and therefore urea-PAGE was 
chosen as the method to analyze levels of RLC phosphorylation.  
 
2.4 Actin-Activated ATPase 
  In the absence of actin, myosin undergoes ATP hydrolysis at a rate that is 
up to 200 times slower than that in the presence of actin [73]. The binding of 
myosin to actin induces conformational changes in the myosin motor domain that 
facilitate the release of phosphate at a much faster rate, and therefore 
significantly increases the myosin ATPase rate [126].  This actin-activation of 
myosin ATPase activity increases until the actin binding sites on myosin become 
fully saturated and myosin ATPase reaches a maximal rate. To determine 
myosin ATPase activity the rate of phosphate production was measured by 
monitoring solution absorbance at 360 nm. Using the Enzyme Linked Inorganic 
Phosphate Assay (ELIPA) kit purchased from Cytoskeleton, Inc. (Denver, CO, 
cat #BK051), myosin enzymatic activity is coupled to the catalytic conversion of 
2-amino-6-mercapto-7-methylpurine ribonucleoside (MESG) to 2-amino-6-
mercapto-7-methylpurine by purine nucleoside phosphorylase (PNP), resulting in 
an absorbance shift from 330-360 nm.  When myosin releases one molecule of 
phosphate, it reacts with MESG to produce one molecule of 2-amino-6-mercapto-
7-methylpurine in an essentially irreversible reaction. Myosin at 0.1 μM was 
mixed with 1 μM actin in the reaction buffer containing 100 mM KCl, 5 mM MgCl2, 
15 mM PIPES, pH7.1, 0.5 mM DTT , and 0.17 mM MESG and 0.54 units PNP.  
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The reaction was initiated by the addition of 1 mM ATP. Solution absorbance was 
measured at 360 nm, with readings taken every 30 sec for 20 minutes. The 
change in absorbance over time was fit to a linear regression, and the myosin 
ATPase rate was determined from the slope of the trendline.  A phosphate 
standard curve was used to convert solution absorbance to nmol phosphate. The 
same reaction buffer was used for generation of the standard curve, with myosin, 
actin and ATP replaced by 0 to 50 nmol phosphate. For each phosphate 
concentration, the solution absorbance was measured at 360 nm after a five 
minute incubation period. 
  For comparisons between two groups (i.e. dephosphorylated and 
phosphorylated, WT and mutant), a two-tailed t-test was used to determine the 
significance of differences in myosin ATPase rates. The p value was calculated 
from the Student’s t-test distribution, and differences were considered significant 
for p<0.05. For comparisons between multiple groups (i.e. dephosphorylated 
myosins, phosphorylated myosins, all myosins), significance of mean ATPase 
values was determined using a one-way ANOVA. The p value was calculated 
using the F distribution, and differences were considered significant for p<0.05.   
 
2.5 In Vitro Motility Assays 
  The in vitro motility assay was developed by Kron and Spudich in 1986 
[67] and provides a method for characterizing the motile behavior of individual 
myosin molecules. In this assay, randomly oriented myosin molecules that are 
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adhered to a glass coverslip translocate fluorescently labeled actin filaments in 
the presence of ATP (Figure 2.2).  Labeled actin filaments are observed using a 
fluorescence microscope. The measurement of actin sliding velocity under 
various biochemical conditions allows for the characterization of the bed of 
myosins. The in vitro motility assay probes the parameters of the actomyosin 
biochemical cycle by eliminating some of the elements that tend to complicate 
the interpretation of muscle fiber studies, such as myofilament lattice spacing, 
cross-bridge recruitment and structural sarcomeric protein components. 
 
 
2.5.1 Epifluorescence Microscopy 
  Fluorescence is a property attributed to organic and inorganic specimens 
that are able to absorb light radiation at a specific wavelength, and subsequently 
re-emit the light at a longer wavelength. Fluorophores are fluorescent chemical 
compounds that can be used as probes to label an element of interest.  
 
 
Figure 2.2: Illustration of the In Vitro Motility Assay 
Monomeric myosin attached to a coverslip surface propel fluorescently labeled actin 
filaments in the presence of ATP. Figure from Jeff Moore. 
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  Fluorescence microscopy utilizes a specific set of chromatic filters to 
manipulate the wavelengths of light used for illumination and detection of the 
specimen. It is crucial to separate the light that travels through the illumination 
pathway (incident on the specimen) from the light that travels through the 
detection pathway (incident on the camera). This is accomplished using a filter 
cube which houses the chromatic filter set (Figure 2.3). The filter cube contains 
an excitation filter and an emission filter that are placed orthongonal to each 
other, and a dichroic beam-splitter that is placed between the two filters. The 
excitation and emission filters allow a narrow range of light to pass through that 
corresponds to the fluorophore’s absorption and emission spectra, respectively. 
A dichroic beamsplitter is a filter that reflects light below a certain cutoff 
wavelength and transmits all light above that wavelength. The cutoff wavelength 
of the dichroic beamsplitter should be between the wavelengths of the excitation 
and emission filters.  
  Unfiltered light from the illumination source passes through the excitation 
filter to the dichroic mirror, where it is reflected upwards through the objective 
and focused on the specimen. Light emitted from the specimen passes through 
the objective and is transmitted through the dichroic and emission filters on to a 
detector. This type of fluorescence microscopy is known as epifluorescence, 
because the excitatory light passes through the objective before reaching the 
specimen, and therefore irradiates the specimen from the viewing side. A much 
greater percentage of excitatory light is transmitted through the specimen than is 
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reflected by the specimen. Therefore epifluorescence has the advantage that 
only reflected excitatory light from the specimen needs to be filtered out of the 
detection pathway, as opposed to the transmitted excitatory light which would be 
of a much higher intensity and result in a reduced signal to noise ratio [127]. 
 
  Our microscope setup consists of a Nikon Eclipse TE2000 inverted 
microscope with a mercury lamp as the epifluorescence illuminator, and a xenon 
lamp as the brightfield transilluminator (Figure 2.3). Light is detected with one of 
two cameras located at the left (IC300 CCD, PTI, Birmingham, NJ) and right 
(iXon3 897 EMCCD, Andor Technology USA, Concord, MA) sideports of the 
.                
Figure 2.3: Fluorescence Microscope and Filter Cube Schematic 
Left: An inverted Nikon EclipseTE2000 microscope utilizes a mercury lamp for 
epifluorescence imaging, and a xenon lamp for bright-field imaging. An IC300 CCD and 
iXon EMCCD (not shown) detect light at either side port of the microscope. A turret that 
houses filter cubes lies in the detection pathway, and in the excitation pathway of the 
mercury lamp.  Right: The filter cube houses a set of chromatic filters that manipulates 
the light traveling through the excitation and emission pathways. Adapted from 
http://media-2.web.britannica.com/eb-media/70/136570-004-F313D891.jpg and 
http://www.olympusmicro.com/primer/techniques/fluorescence/images/fluorescencecub
e2.jpg 
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microscope. The set of chromatic filters used for motility assay experiments 
aimed at visualizing TRITC fluorophores coupled to actin are a 545/30 nm 
excitation filter, a 565 nm long pass dichroic, and a 600/45 nm emission filter.  
 
2.5.2 Standard Motility Assay Protocol 
  Coverslips were coated with 1% nitrocellulose to permit the attachment of 
myosin molecules to the coverslip surface. Glass coverslips were plasma 
cleaned, then dipped in a solution of 1% nitrocellulose in isoamyl acetate and 
allowed to dry. A flow chamber was constructed by attaching two opposite sides 
of the coverslip to a glass microscope slide with double stick tape. The depth of 
the flow cell is equal to the thickness of the double stick tape (100 μm). The 
volume of the constructed flow chambers was approximately 15 μL. Assay 
conditions are determined by the experimental solutions added to the flow cell.  
  Damaged myosin heads that are unable to bind and release from actin 
were removed during the sample preparation by centrifugation prior to light 
miscroscopy. Then, myosin suspended in myosin buffer was mixed with 1.1 μM 
actin and 1 mM ATP and centrifuged in an Airfuge for 25 min at 100,000 × g. The 
concentration of myosin in the supernatant was determined using the Bradford 
Assay, and myosin was diluted to a concentration of 100 μg/ml in myosin buffer.  
  Solutions were added to the flow chamber in 30 μl volumes. One volume 
of myosin solution was added to the flow chamber and incubated for 2 min, 
during which time myosin is adsorbed to the coverslip surface. The chamber was 
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then washed with one volume of 1 mg/ml BSA in myosin buffer to fill any 
remaining gaps on the coverslip surface and thus prevent non-specific binding to 
the coverslip surface. After 1 minute BSA incubation, the chamber was washed 
with two volumes of actin buffer (55 mM KCl, 25 mM BES, 5 mM EGTA, 4 mM 
MgCl2, and 1 mM DTT).  To block any inactive myosin present on the coverslip 
surface, 1 μM unlabeled actin in actin buffer was added to the flow cell and 
allowed to bind to the myosin for 2 minutes. The chamber was washed with two 
volumes of actin buffer containing 1 mM ATP, followed by four volumes of actin 
buffer with no ATP. TRITC-labeled actin filaments (~ 10 nM) in actin buffer were 
then added and allowed to bind to the myosin in the absence of ATP for 1 min. 
The movement of actin was initiated by the addition of 1 mM ATP in actin buffer 
with 4 mg/mL glucose, oxygen scavengers (17 units/ml glucose oxidase and 125 
units/ml catalase) and 0.5% methylcellulose. Actin filament movement was 
observed at 30oC with an intensified charge-coupled device camera (IC300; PTI, 
Birmingham, NJ, USA). Video images were captured using a PIXCI® EL1 frame 
grabber and XCAP software (Epix, Inc., Buffalo Grove, IL, USA), and two or more 
movies per flow cell were analyzed.  
  Modifications to the in vitro motility assay allow for the characterization of 
different myosin properties. In the following sections, experimental variations of 
the in vitro motility assay are discussed, and corresponding protocol 
modifications and data analysis are presented. 
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2.5.3 Unloaded Motility Assays 
Introduction 
  For unloaded motility assays standard motility buffers were used and no 
modifications were introduced to the standard protocol. Actin sliding velocity was 
measured to assess and compare myosin activity. The unloaded actin sliding 
velocity measured in this assay is referred to as the observed maximal sliding 
velocity (Vmax) and provides a reference for assessing myosin activity.  
Data Analysis 
  For each experimental preparation (one flow cell), at least two video 
segments were recorded, and actin sliding velocity was determined by averaging 
the velocities of at least 25 actin filaments. Actin filament velocities were 
measured using MTrackJ, a plugin supported by the public domain image 
processing program, ImageJ (U. S. National Institutes of Health, Bethesda, 
Maryland, USA). MTrackJ allows for the manual tracking of moving objects within 
an image sequence. Actin filament velocity was determined by tracking the 
distance the filament traveled between 10 to 30 consecutive video frames taken 
at one second intervals.  
  The maximal sliding velocity (Vmax) produced by each myosin type was 
determined by the averaging the actin sliding velocities measured from 4-8 
experimental preparations.  A two-tailed t-test based on the mean and standard 
deviation of sliding velocities was used to determine significance between Vmax 
values. The p value was calculated from the Student’s t distribution, and 
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differences were considered significant for p<0.05. Differences between maximal 
sliding velocities of multiple groups was determined from the F statistic of a one-
way ANOVA. The p value was calculated using the F distribution, and differences 
were considered significant for p<0.05.   
 
2.5.4 Frictional Loading Motility Assays 
Introduction 
  A major factor that affects heart performance is the load experienced by 
the heart. In the previous sections, unloaded assays that measure velocity and 
ATPase were described. When there is no load imposed on the muscle, it does 
not produce any force and will contract at maximal velocity. Unloaded conditions 
are not physiological but provide a reference level of contractility for our 
experiments. Loaded in vitro motility assays mimic more physiologically relevant 
conditions and were performed for myosins containing various RLC.  
  When the load imposed on a muscle is equal to or greater than the 
maximal force generating capabilities of the muscle, the muscle is unable to 
shorten as it contracts. Since the afterload experienced by the heart is less than 
the maximal force output of the myocardium, the ventricular muscle can produce 
force equal to the afterload while shortening in order to eject blood. Using loaded 
in vitro motility assays, myosin load-dependent behavior mimicking that in situ 
was characterized where myosin generates both force and motion, and 
consequently power. 
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  To determine mutant and WT myosin maximal force generation with and 
without phosphorylation we employed a frictional loading assay where α-actinin, 
a non-motor actin-binding protein, was used as a mechanical load in the 
standard in vitro motility assay (Figure 2.4) [57, 155]. Actin filament motility is 
reduced in the presence of α-actinin, a protein that weakly and transiently binds 
to actin [38, 68]. As α-actinin surface concentration increases, actin filaments 
experience a greater opposing force to the myosin driving force, and actin sliding 
velocity decreases. The myosin driving force can be estimated by modeling the 
relationship between the α-actinin concentration and actin sliding velocity [43].
 
Protocol Modifications for Frictional Loading 
  The procedure for frictional loading motility assays was identical to the 
standard in vitro motility assay except with one modification. The initial incubation 
of 100 μg/mL myosin in myosin buffer was mixed with varying amounts of α-
actinin before being added to the flow chamber. After incubation for one minute, 
 
Figure 2.4: Diagram of the Frictional Loading Motility Assay Coverslip Surface 
Myosin and actin binding proteins (ABPs) attached to the coverslip surface interact with 
fluorescently labeled actin filaments. Myosin molecules exert a driving force on the actin 
filament propelling it forward while ABP interactions put a load on the actomyosin 
complex and oppose filament motion. ABP detachment occurs either kinetically or 
mechanically. Figure from Jeff Moore. 
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myosin and α-actinin were bound to the coverslip surface. BSA was added next 
and the procedure was completed as described in section 2.5.2. 
 Data Analysis 
  For each flow cell, at least two video segments were recorded, and actin 
filaments were tracked for 10 to 30 consecutive video frames taken at one to five 
second intervals. The actin sliding velocity was determined from 25 to 30 actin 
filaments for each flow cell. This average velocity and its associated α-actinin 
concentration represents one data point in a single experiment. RLC depletion 
and reconstitution was performed on at least three different PC myosin 
preparations, and an experimental data set incorporating a range of α-actinin 
concentrations was obtained for each preparation. A weighted average (based 
on the number of filaments analyzed) of the velocities from all data sets was 
calculated and are plotted in Figure 3.6.  All parameters determined from model 
fitting were determined from the average data set.  
  In the absence of an exogenously added load, the myosin driving force 
(Fd) propels actin at maximal velocity (Vmax). In the frictional loading motility 
assay, α-actinin provides an exogenous load (Fload) to the actin filament that 
opposes the myosin driving force. Actin sliding velocity (V) is determined by the 
balance of the forces acting on the actin filament: 
 
ܸ ൌ 	௏೘ೌೣ	ൈሺி೏ିி೗೚ೌ೏ሻி೏              (Eq. 1) 
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The frictional load exerted by α-actinin, α in Eq. 2, in the motility assay is given 
by: 
ܨ௟௢௔ௗ 	ൌ 	 	௏	ൈ	఑	ൈ	఍	ൈ	௅	ൈ	௥	ൈ	௞ಲ	ൈ	ఞ	ൈ	ሾఈሿ
ఱ/మ
௞ವ	ൈ	ሺ௞ಲ	ൈ	ఞ	ൈ	ሾఈሿయ/మ	ା	௞ವሻ      (Eq. 2) 
 
where κ is the system compliance associated with the α-actinin and the α-actinin 
–actin linkages, L is the length of a typical actin filament, r is the reach of an α-
actinin protein to bind to an actin filament, kA is the second-order rate constant 
for α-actinin attachment to actin, kD is the α-actinin detachment rate, and ζ and χ 
are constants that define the surface geometry of α-actinin on the surface [43].  
  A model describing actin sliding velocity (V) dependence on α-actinin 
concentration ([α]) is derived by substituting Eq. 2 into Eq. 1. This model was fit 
to the data obtained from frictional loading motility assays according to Eq. 3: 
 
ܸ ൌ ௏೘ೌೣ	ൈ	ி೏
ி೏ାቆೇ೘ೌೣ	ൈഉ	ൈ	അ	ൈ	ಽ	ൈ	ೝ	ൈ	ೖಲ	ൈ	ഖ	ൈ	ሾഀሿ
ఱ/మ
ೖವ	ൈ	ሺೖಲ	ൈ	ഖ	ൈ	ሾഀሿయ/మ	శ	ೖವሻ
ቇ
          (Eq. 3) 
 
The derivations of Eq. 2 and 3, values used for model fitting, and an explanation 
of model limitations are provided in Greenberg and Moore, 2010 [43].   
  The program SigmaPlot (Systat Software Inc., San Jose, CA) was used to 
fit data sets to Eq. 3 with a nonlinear least squares fitting algorithm. Errors in the 
least squares fit were used to determine coefficient parameters and standard 
errors for maximal sliding velocity (Vmax) and isometric force (Fd) of the randomly 
oriented myosin ensemble. Significance between Fd values was examined using 
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a one-tailed t-test. First, F tests were performed to verify that two groups had 
equal variances. The t value was determined by calculating the pooled estimate 
of the variance using the standard errors of the coefficients from the least 
squares fit. The pooled variance is given by: 
ܵ௉ଵଶ ൌ ܵܧଵ
ଶሺ݊ଵ െ 2ሻ ൈ ݊ଵ ൅ ܵܧଶଶሺ݊ଶ െ 2ሻ ൈ ݊ଶ
݊ଵ െ ݊ଶ െ 4  
where SEx and nx  represent the standard error of the coefficient and number of 
data points defining the curve, respectively. The t value is then given by: 
ݐ ൌ ݔଵ െ ݔଶ
ටቀܵ௉ଵଶ݊ଵ െ
ܵ௉ଵଶ݊ଶ ቁ
 
The degrees of freedom is equal to n1 + n2 – 4 [37]. A p value was obtained using 
the Student’s t distribution, and differences in Fd values were considered 
significant for p<0.05. 
Comparison of Loaded In Vitro Motility Assay Models 
  In the loaded motility assay, an actin binding protein (ABP) bound to the 
coverslip surface is utilized as a load bearing molecule. When the ABP binds to 
actin, it provides an exogenous load to the actin filament and actomyosin 
complex. The α-actinin protein has been one of the most widely used ABP 
employed in the loaded in vitro motility assay [11, 41, 57, 75].  The properties of 
α-actinin and the α-actinin–actin bond are well characterized which allowed for 
the derivation of the frictional loading model described above. In a recent 
publication by Aksel et al., a new version of the loaded motility assay is described 
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that utilizes a utrophin-based ABP to provide an opposing load to the actomyosin 
[2]. The authors use this assay to characterize the behavior of myosin S1 
constructs on the coverslip surface (as opposed to full length myosin). Below is a 
comparison of the two different loaded motility assays using either α-actinin or 
utrophin as the load bearing ABP. 
  In the utrophin-based assay, the authors express a short construct of the 
human cardiac β-myosin S1 (sS1). Characterizing human isoforms of myosin is a 
major advantage for studying disease-linked mutations; however, the sS1 
construct lacks the RLC binding region and therefore cannot be used to study 
mutations and phosphorylation of the RLC. The expressed myosin sS1 and 
utrophin constructs are engineered with a short C-terminal peptide which binds to 
an anchoring protein that is attached to the motility assay surface [2]. This 
reduces variability in the linkage of myosin and utrophin to the coverslip surface. 
The utrophin construct used in the assay contains an actin binding domain and a 
single spectrin repeat; it was designed to be similar in size to the myosin sS1. In 
contrast, an α-actinin monomer contains an actin binding domain, four spectrin 
repeats, and an EF hand domain [27]; it is closer in size to full length myosin. 
The choice of ABP used in loaded motility assays must have a similar reach as 
the myosin on the surface in order for both myosin and ABP to be accessible to 
the actin filaments. Based on the mechanical differences between the two 
proteins and their bond to actin, it is expected that the nature of the load 
produced by α-actinin and utrophin will differ. 
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  In a loaded motility assay, when an ABP binds to an actin filament it 
becomes stretched as the myosin driving force pulls the actin filament away. 
Strain accumulates in the ABP while it is attached to the actin filament, and it 
produces a load opposing the myosin driving force. The load imposed by a single 
ABP will depend on the elasticity of the ABP and the ABP–actin bond, as well as 
the duration of the ABP–actin bond.  
  For the loaded motility assays presented in this work, the load exerted by 
α-actinin is modeled as being velocity dependent due to the elastic nature of the 
α-actinin protein. An α-actinin molecule will exert a greater force on an actin 
filament the more it is stretched, and a faster moving actin filament will stretch 
the α-actinin molecule further during the kinetic lifetime of the α-actinin–actin 
bond.  Therefore the load exerted by α-actinin is dependent on actin sliding 
velocity. The load produced by a certain concentration of α-actinin is defined in 
Eq. 2 which uses parameters for α-actinin stiffness and the duration of the α-
actinin–actin bond that have been characterized in the literature. The model uses 
a first order approximation for α-actinin–actin detachment rate; this makes the 
simplifying assumption that the detachment rate of α-actinin is independent of 
strain. Characterization of the strain dependence of the α-actinin–actin bond 
would allow for a better approximation of the kinetic lifetime of the bond as it 
changes with load. Incorporation of this data (if it becomes available) would 
provide higher order corrections to the model described in Eq. 2 and 3. 
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  Aksel et al. show that the actin filaments in the utrophin-based loaded 
motility assay are either moving at maximal velocity or are stopped. This implies 
that utrophin stops an actin filament immediately upon binding, which makes the 
assumption that utrophin (and the utrophin–acitn bond) is not elastic or that 
elasticity is immediately pulled out of the protein and bond upon binding to actin. 
This is a valid assumption given the small size of the utrophin construct. For each 
utrophin concentration analyzed, Aksel and colleagues take into account the 
amount of time each filament spends moving versus stopped, as well as the 
average filament velocity as a result of this behavior. From this relationship, the 
authors are able to define a dissociation constant for the utrophin–actin 
interaction in the presence of myosin sS1 [2]. The data can be interpreted as a 
binding equilibrium between utrophin and actin that will change based on the 
force exerted on actin by myosin sS1 on the surface. Myosin that produces a 
higher force on an actin filament will increase the detachment rate of utrophin, 
and therefore yield a larger dissociation constant (i.e. the concentration of 
utrophin that corresponds to an equilibrium between motile and stopped actin 
filaments). Therefore the load exerted by the utrophin construct on an actin 
filament is interpreted as being dependent on the strain dependence of the 
detachment rate.  
  Both versions of the loaded in vitro motility assay make assumptions 
about the nature of the ABP used. For α-actinin, it is assumed that the strain 
dependence of the detachment rate is negligible compared to the effects from 
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protein’s elastic properties. For utrophin, it is assumed that elasticity of the 
protein and bond to actin is negligible compared to the strain dependence of the 
detachment rate. Both assumptions are well suited to the nature of the ABP and 
interpretation of the data. An advantage of using the α-actinin loading model is 
that α-actinin surface concentration can be converted to a loading force based on 
physiological parameters of α-actinin and the α-actinin–actin bond that have 
been characterized in the literature. This allows for the characterization of 
myosin’s load dependent behavior and the construction of myosin power output 
curves.  
 
2.5.5 Power Transformation 
Introduction 
  Cardiac power output represents the rate at which the heart can perform 
work (i.e. eject blood) and is a critical indicator of heart’s ability to maintain 
cardiac output as heart rate changes. Power output can be determined from the 
force-velocity relationship of muscle. This relationship is a fundamental aspect of 
muscle contraction which demonstrates that force production increases as 
filament velocity decreases because myosin cross-bridges have more time to 
attach to the filament (and more time before detachment) leading to a greater 
population of bound myosin heads and increased force production of the muscle. 
The transformation of frictional loading motility assay data to myosin power 
output is described in the next section. 
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Data Analysis 
  Data from frictional loading motility assays was transformed to represent 
myosin power output as a function of frictional load.  First, [α-actinin] for each 
data point was converted to a frictional loading force, Fload, using Eq. 2. Force-
Velocity data (Fload, V) was obtained from the transform. At a frictional load 
equivalent to the myosin isometric force (Fload=Fd), velocity is equal to zero (see 
Eq. 1).  Isometric force values obtained from frictional loading assays were 
included in the transformed data set (Fd, 0).   
  Power is the product of force and velocity.  Force-velocity data were 
transformed to force-power data by taking the product of force and velocity, and 
then plotting the power versus force. Power curves were constructed by fitting 
the force-power data (Fload, P) to the empirically derived Hill equation for power 
given by [50]:  
 
ܲ ൌ 	ܾ	 ൈ ܨ௟௢௔ௗ	 ൈ ቀ ிబା௔ி೗೚ೌ೏ା௔ െ 1ቁ   (Eq. 4) 
 
where Fo is the isometric force and a and b are constants. The equation was fit 
with a least squares fitting algorithm. The load at which maximal power output 
occurs was calculated by setting the derivative of the Hill power equation equal to 
zero and solving for Fload. This value was substituted into Eq. 4 to determine 
maximal power output. Errors in these parameters were determined from the 
errors in the least squares fit of Eq. 4.  
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2.5.6 Inhibition of Loaded Motility by ADP 
 
Introduction 
  Load can only affect the transitions of the actomyosin biochemical cycle 
that occur while myosin is strongly bound to actin. The cross-bridge attachment 
time is set by the rates of ADP release and ATP binding, since they are the 
slowest steps in the attached state. The rate limiting step of the cycle is the 
release of ADP from the active site [124], and it has been established that the 
kinetics of the ADP release step are sensitive to load [95].  When a load is 
applied to muscle, the ADP release rate slows and actomyosin detachment is 
prolonged.  ADP is a competitive inhibitor of ATP for the binding pocket in the 
rigor state when there is no nucleotide bound. In the following experiments, 
exogenous ADP was added to loaded in vitro motility assays to probe the rate 
limiting step of biochemical cycle, and study the effects of RLC modifications on 
the exchange of ADP for ATP in the myosin binding pocket under load. 
Protocol Modifications for ADP Binding Studies 
  The following modifications were made to the standard in vitro motility 
assay protocol: For the initial incubation step, 1.5 μg/mL α-actinin was mixed with 
100 μg/mL myosin and then added to the flow chamber. For the final incubation 
step, the motility buffer was supplemented with 2 mM ADP. Experiments were 
also performed in the absence of ADP. The concentration of 2 mM ADP is higher 
than physiological levels of ADP that accumulate in cardiac muscle, which is 
typically 20-50 μM [55]. This high concentration was chosen to provide an excess 
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of ADP in relation to ATP, which is present at a concentration of 1 mM, to ensure 
that ADP could effectively compete with ATP and that the effects of exogenous 
ADP on loaded motility could be resolved. 
Data Analysis  
  For these experiments, an automated analysis was used to track the 
position of actin filaments in motility assay movies, as opposed to the previously 
employed manual tracking method. Automated data analysis was carried out 
using the ImageJ plug-in wrMTrck (written by J.S. Pedersen, 
http://www.phage.dk/plugins/wrmtrck.html).  The wrMTrck plug-in utilizes 
centroid-tracking algorithms to automatically locate and track objects in an image 
sequence, and reports object velocities as well as other statistics. Filters were 
put in place to exclude actin filaments that displayed certain behaviors from the 
analysis. For example, actin filaments were excluded from analysis if the filament 
exceeded thresholds pertaining to actin filament length and impaired filament 
mobility, such as stalling, circling, or non-directional fluctuations. Video segments 
were recorded at a rate of three frames per second and a minimum of two 
movies were analyzed per flow cell. Actin filament sliding velocity was then 
determined by the automated analysis for each flow cell.  
  For each myosin studied, two experiments were performed, both 
originating from the same PC myosin preparation and RLC exchange procedure.  
Average actin sliding velocities were determined from two experiments and a 
minimum of 50 actin filaments tested. A two-tailed t-test based on the mean and 
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standard deviation of sliding velocities was used to determine significance 
between average velocities. The p value was calculated from the Student’s t 
distribution, and differences were considered significant for p<0.05. 
  
73 
CHAPTER 3 – RESULTS: 
Effects of Physiological and Pathological RLC Modifications 
 
Introduction 
  The regulatory light chain (RLC) of myosin provides structural support to 
the myosin neck region which acts as a lever arm during the myosin 
powerstroke. During the cyclical interaction of myosin with actin filaments, small 
conformational changes in the myosin catalytic domain are amplified by the lever 
arm to produce force and motion [106, 145]. In addition to serving a mechanical 
role in the transmission of contractile force, the RLC can also fine tune the 
kinetics of the actomyosin. Phosphorylation is a naturally occurring post-
translational modification of the RLC that plays a role in modulating myosin 
cycling kinetics [42]. It has been established that RLC phosphorylation can 
increase muscle fiber activation at submaximal Ca2+ levels and the rate of force 
development [23], however a growing body of evidence suggests that RLC 
phosphorylation has a major influential role in cardiac muscle function, torsion, 
and disease [122]. Studies of muscle at the fiber and tissue level have begun to 
elucidate the range and complexity of actions exhibited by RLC phosphorylation, 
however the molecular based changes induced by RLC phosphorylation on the 
single myosin motor remains to be determined.  
  Several genetic mutations identified in the RLC lead to familial 
hypertrophic cardiomyopathy (FHC) [5]. FHC is characterized by left ventricular 
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hypertrophy, however the pattern of cardiac remodeling and symptoms that 
accompany disease vary widely. The phenotype is determined by the specific 
causal mutation, and may include chest pain, shortness of breath, diastolic filling 
abnormalities, arrhythmias, but often results in sudden cardiac death in the 
absence of any other symptoms [21]. Given that the clinical presentation and 
prognosis of the disease depends on the specific mutation, a detailed 
understanding of the pathogenesis of each mutation is crucial to the development 
of therapeutic agents. Two genetic mutations located in the N-terminal lobe of the 
RLC, N47K and R58Q, display drastically different clinical FHC phenotypes. 
N47K is associated with late onset, rapidly progressing mid-ventricular 
hypertrophy [6], while R58Q is associated with early onset hypertrophy and 
sudden cardiac death [34]. However both mutations result in loss of Ca2+ binding 
to the cationic binding site of the isolated RLC, and a reduction of myosin motility 
under load [41].  Phosphorylation was shown to restore Ca2+ binding ability to the 
R58Q RLC [139].  
  The studies presented in this chapter explore the effects of physiological 
and pathological RLC modifications on the cardiac β-myosin motor protein. We 
hypothesized that phosphorylation of the RLC could compensate for mutation-
induced decreases in myosin contractility. In vitro motility assays were employed 
to test this hypothesis and characterize alterations in actomyosin interactions that 
occur at the most fundamental level of muscle contraction.  
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3.1 RLC Phosphorylation 
 
    Bacterially expressed WT, N47K and R58Q hvRLCs were 
phosphorylated by smooth muscle MLCK in order to study the naturally occurring 
post-translational modification and mutational variants of the RLC. 
Phosphorylation of hvRLCs was performed alongside mock reactions under 
identical conditions except without the presence of CaM-MLCK. After 1 hour 
incubation at room temperature, hvRLC samples were run on 8 M urea 10% 
PAGE to determine the extent phosphorylation (Figure 3.1). Addition of a 
phosphate group to the RLC adds a negative charge to the protein, resulting in a 
more acidic isoelectric point. Therefore phosphorylated RLC migrates further 
towards the cathode than its dephosphorylated counterpart in urea-PAGE.  As 
can be seen in Figure 3.1, there was no evidence of phosphorylation in mock 
reactions. 
  
     
                   WT                                   N47K                               R58Q          . 
           Mock            Phos             Mock             Phos             Mock         Phos 
 
Figure 3.1: Phosphorylation of hvRLCs by MLCK  
Charge separation of dephosphorylated and phosphorylated bacterially expressed 
human ventricular RLCs is shown on an 8 M urea 10% polyacrylamide gel. Due to a 
more acidic isoelectric point phosphorylated RLCs migrate further than their respective 
dephosphorylated counterparts. Charge differences introduced by the mutations can 
also be resolved. 
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  Regulatory light chains were readily phosphorylated as indicated by 
increased mobility in urea-PAGE. Densitometry analysis showed phosphorylation 
levels of 95.7 ± 3.6% for WT RLC, for 98.4 ± 1.6% N47K RLC, and 87.4 ± 0.8% 
for R58Q RLC (given as the mean ± SE from 4-5 preparations).  Phosphorylation 
of the R58Q light chain was consistently slower when compared to WT and N47K 
light chains. Therefore, the reaction incubation time was chosen based on the 
slower kinetics of the enzymatic reaction for the R58Q RLC substrate, which 
assures complete phosphorylation of each light chain. In addition, the R58Q light 
chain was more susceptible to proteolytic digestion, as evidenced by the 
existence of smaller molecular weight fragments appearing with storage times 
greater than two months. It is possible that increased proteolytic susceptibility 
and the decreased rate of phosphorylation were caused by structural alterations 
induced by the R58Q mutation, which could potentially alter the affinity of MLCK 
and/or proteases for the mutant RLC.  
  The N47K RLC migrated as a double band in urea-PAGE, but as a single 
band in SDS-PAGE (see Figures 3.1 and 3.2), indicating the existence of charge 
variants of the N47K RLC. Both charge variants were consistently 
phosphorylated. The charge variants may arise from acetylation of the lysine 
residue introduced by the mutation, or from deamidation of asparagine residues 
that flank the phosphorylation site at serine15 [119]. Both processes are known 
to occur in bacterial expression systems. Following mock or phosphorylation 
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reactions, hvRLCs were kept on ice for 1 to 3 hours and then reconstituted onto 
porcine cardiac myosin.  
 
3.2 RLC Depletion and Reconstitution 
  Porcine cardiac (PC) myosin was chosen to study the effect of RLC 
modifications on β-MHC performance. PC myosin depleted of its native RLC 
following treatment with triton X-100 and CDTA (Figure 3.2; lane 2) was 
recombined with dephosphorylated or phosphorylated hvRLCs at a 1:3 molar 
ratio. Myosin samples were analyzed using 12% SDS-PAGE (Figure 3.2). The 
level of RLC depletion was determined to be 84.8 ± 5.8% based on 4 
preparations of PC myosin. MHCs were fully reconstituted with hvRLCs.  
 
   
 
Figure 3.2: RLC Exchange on PC β-Myosin 
SDS-PAGE of PC myosin RLC exchange reaction shows MHC, ELC and RLC bands 
from PC myosin, PC RLC depleted myosin (85% depletion), and PC RLC depleted 
myosin fully reconstituted with hvRLCs in the dephosphorylated and phosphorylated 
states. 
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3.3 Actin-Activated ATPase  
  Actin-activated ATPase rates were measured under conditions similar to 
those of the motility assay to assess potential differences in the enzymatic 
activity between WT and mutant myosins in the phosphorylated or 
dephosphorylated state. Actin activated ATPase measurements provide valuable 
information about alterations in actin filament velocity as the rate of actin sliding 
velocity in the motility assay is directly proportional to the myosin ATPase rate. 
The actin-activated ATPase assay was performed as described in section 2.3.2.  
  Myosin at 0.1 μM and actin at 1 μM were mixed in solution with 1 mM 
ATP. The coupled reaction measuring the amount of phosphate generated by 
ATP hydrolysis was linear with time and standardized to convert absorbance 
units to nmol phosphate (Figure 3.3). 
 
Figure 3.3: Linear Regression Fit to Solution Absorbance Data 
The solution absorbance of an ATPase reaction was monitored at 360 nm for 20 
minutes. Absorbance units were converted to nmol phosphate, and a linear regression 
was fit to the data to provide the rate of phosphate release. The representative trace 
shown is from data on R58Q phosphorylated myosin.
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  The slope of a regression line gives the rate of phosphate release from 
myosin in nmol/s. The actin-activated myosin ATPase rate is derived from the 
phosphate release rate by accounting for the amount of myosin present in 
solution. Table 1 shows the average myosin ATPase rate from three experiments 
in units of nmol phosphate per nmol myosin per minute. The actin-activated 
myosin ATPase was not significantly altered by mutations or phosphorylation of 
RLC. 
 
 
3.4 In Vitro Motility Assays  
  Motiltiy assays provide a method for investigating the molecular 
mechanisms of muscle contraction, and like any technique has a set of 
limitations. Actin filament sliding is unidirectional due to the polarity of the actin 
filament, but will follow a winding path rather than a straight line. This is due to 
the randomly oriented myosins on the coverslip surface that the actin filament 
encounters, and is a major source of scatter in the sliding velocities of individual 
filaments. For this reason it is necessary to use an average value from a 
minimum of 10 filaments [132]. Another source of heterogeneity stems from the 
Table 1: Actin-Activated Myosin ATPase Rates
 WT 
WT 
Phos N47K 
N47K 
Phos R58Q 
R58Q 
Phos 
ATPase (min-1) 7.067 6.500 6.375 8.667 5.700 6.775 
± Std Error ± 1.241 ± 0.836 ± 0.897 ± 1.304 ± 0.634 ± 0.844
Shown are mean ATPase rates ± SE from three experiments. There are no significant 
differences in myosin ATPase rates for any myosin. 
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nature of the linkage between the coverslip surface and the myosin molecules. In 
experiments utilizing myosin S1-S2 fragments where the S2 portion was 
truncated in various positions, actin sliding velocity decreased as S2 was 
shortened [96]. Furthermore, damaged myosin heads that form rigor-like bonds 
may introduce a resistance to the filament sliding velocity, although care is taken 
to reduce the number of damaged myosins during preparation. These factors 
cause variation in the measurement of actin sliding velocity and give rise to the 
inherently noisy nature of the motility assay. Despite these limitations the motility 
assay is effective in characterizing various fragments, chemical modifications and 
mutations of myosin and actin as well as other regulatory proteins.  
 
3.4.1 Unloaded Sliding Velocity 
  The maximal actin sliding velocities of myosin bearing WT, N47K or R58Q 
RLC in the dephosphorylated and phosphorylated states were measured in the 
unloaded in vitro motility assay (Figure 3.4). Observed values at 100 μg/mL 
myosin were Vmax(WT)=0.73 ± 0.02 μm/s, Vmax(WT Phos)=0.78 ± 0.02 μm/s, 
Vmax(N47K)=0.68 ± 0.05 μm/s, Vmax(N47K Phos)=0.77 ± 0.05 μm/s, 
Vmax(R58Q)=0.70 ± 0.03 μm/s, and Vmax(R58Q Phos)=.80 ± 0.03 μm/s. 
There was no significant difference in Vmax values between myosins bearing 
dephosphorylated RLCs (p>0.45), or between myosins bearing phosphorylated 
RLCs (p>0.84), as determined by one-way ANOVA. Additionally, differences in 
Vmax values for myosin with dephosphorylated and phosphorylated RLC was not 
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significantly different for the WT RLC (p>0.10) or for the N47K RLC (p>0.18). 
However, there was a significant difference in the Vmax values for myosin bearing 
R58Q RLC in the dephosphorylated and phosphorylated states (p<0.05) as 
determined by a two-tailed Student’s t-test assuming equal variances.  
 
 
3.4.2 Myosin Isometric Force  
  The frictional loading motility assay was used to study myosin force 
generation. In this variation of the in vitro motility assay, a low affinity actin 
binding protein, α-actinin, was added to the coverslip surface along with myosin. 
Binding of α-actinin to actin imposes a viscoelastic drag on the actomyosin. This 
means the drag force imposed is time dependent, and will depend on the kinetic 
 
Figure 3.4: Maximal Actin Sliding Velocity 
Average measurements (± SE) from unloaded motility assays of dephosphorylated and 
phosphorylated WT, N47K and R58Q myosins show no significant difference between 
WT and mutant myosins. Phosphorylation of R58Q RLC significantly increased velocity.
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lifetime of the α-actinin – actin bond as well as actin filament velocity. Frictional 
loading motility assays were employed to compare the force producing 
capabilities of myosin bearing dephosphorylated and phosphorylated hvRLCs. 
Data from frictional loading motility assays were fit to the viscoelastic model 
provided in Eq. 3, which models the relationship between actin sliding velocity 
and the load imposed by α-actinin. 
 
  The isometric force of myosin (Fd) was determined from this relationship. 
In the absence of load, the N47K and R58Q myosins propelled actin at a similar 
velocity as WT myosin. However, in the presence of an α-actinin-induced 
frictional load, N47K and R58Q mutant myosins moved actin at slower velocities  
 
Figure 3.5: Frictional Loading Motility Assay of WT and Mutant Myosins 
Actin velocity decreases with increasing α-actinin on the surface. Measured velocities 
from a single experimental data set are shown above. N47K and R58Q myosins cannot 
move actin as fast as WT myosin under the load produced by α-actinin. Data were fit to 
the viscoelastic model provided in Eq. 3. 
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than WT myosin. This trend 
was seen for the individual 
experimental data sets (Figure 
3.5) as well as for the averaged 
data sets (Figure 3.6). This 
resulted in significantly 
decreased force production for 
both mutations compared to 
WT (p<0.05), consistent with 
previous results [41].  
   Upon MLCK-induced 
phosphorylation of the RLC, we 
see increased actin sliding 
velocity for WT and mutant 
myosins at all loads measured 
(Figure 3.6A-C), resulting in 
increased force production for 
myosins containing 
phosphorylated RLC. 
Figure 3.6: Frictional Loading Assays Comparing RLC Phosphorylation States 
Average actin sliding velocities and SEs are plotted as a function of α-actinin added to the 
motility assay surface. Average velocity is determined from 3-4 experiments. Panels show 
myosin bearing RLCs in the dephosphorylated (circles, solid line) and phosphorylated
(triangles, dashed line) states for A) WT, B) N47K, and C) R58Q RLCs. The fit of WT data 
to Eq. 3 (solid black line) is shown in panels B and C to aid in visual comparison.
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Isometric force values calculated from the model fit were Fd(WT)= 1908 ± 259 
pN, Fd(WT Phos)= 2644 ± 239 pN, Fd(N47K)= 1314 ± 159 pN, Fd(N47K Phos)= 
1992 ± 302 pN, Fd(R58Q)= 1129 ± 110 pN, and Fd(R58Q Phos)= 1817 ± 283 pN.  
Phosphorylation-based increases in force were observed for each individual 
experimental preparation as well as for the averaged data (Figure 3.7 and 3.8).   
 
   The data from the motility assays presented above display a fair amount 
of scatter. This is in part due to the inherent noise associated with the motility 
assay, and in part due to the averaged data set stemming from three different 
myosin preparations (each originating from a different pig heart, and undergoing 
subsequent RLC exchange procedures). In addition, the slow nature of β-myosin, 
especially when working against a load imposed by high α-actinin surface 
concentrations, results in actin sliding velocities that approach zero, which limits 
 
Figure 3.7: Trend of Increased Isometric Force Production with Phosphorylation 
Myosin isometric force determined from nonlinear regression least squares fitting of data 
sets from individual experimental preparations shows a trend of increased force 
production with RLC phosphorylation. Error bars are given by the standard error of the 
coefficient from the least squares fit.  
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resolving power. To overcome the variance in the data and maintain confidence 
in parameter estimates, three individual experimental curves were defined for 
each myosin, each with a high number of data points defining the curve. The 
trends of the individual experiments are the same for the average data sets 
(Figure 3.7 and 3.8). Most importantly, the statistical analysis used was suitable 
for the comparison of coefficient parameters determined from nonlinear 
regression models. In addition, when the chosen statistical analysis method (see 
section 2.5.4) was compared to two other methods for determining significance of 
parameters in nonlinear regression models, the method of choice returned less 
significant values indicating it is a more stringent statistical analysis method [16].   
  Myosin isometric force values are presented in Figure 3.8. N47K and 
R58Q mutations reduced β-myosin force production to 69% and 59% of WT 
myosin force, respectively. Phosphorylation of the RLC resulted in a 39%, 
increase in force production for WT myosin, as well as a 52% and 62% increase 
in force for N47K and R58Q myosins, respectively. Differences between the 
isometric force of myosin bearing dephosphorylated or phosphorylated RLC were 
significant (p<0.05) for WT, N47K and R58Q light chains. The phosphorylation 
induced increase in force production for myosin bearing N47K and R58Q light 
chains restored both mutations to WT dephosphorylated force levels. Figure 3.8 
demonstrates that RLC phosphorylation enhances force output of the cardiac β-
myosin motor in health and disease.  
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3.4.3 Myosin Power Output 
  The heart must generate power during systole in order to efficiently pump 
blood against the load imposed by aortic blood pressure. Cardiac power output 
can be modulated by altering the intrinsic power of the myosin molecule. To gain 
insight into how myosin power output is affected by modifications of the RLC at 
the molecular level, data from frictional loading motility assays were transformed 
to reflect load and power using Eq. 2. Power curves were generated by fitting the 
data to the Hill equation for power (Eq. 4), and are plotted in Figure 3.9.  
 
Figure 3.8: Average Myosin Isometric Force  
Nonlinear regression least squares fitting of averaged data to Eq. 3 estimates the 
isometric force of the bed of myosins. Error bars are given by the standard error of the 
coefficient from the least squares fit. Force production was significantly reduced for N47K 
(p<0.05) and R58Q (p<0.01) myosin compared to WT myosin. Phosphorylation of the 
RLC resulted in significantly higher force for all myosins (p<0.05).  
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  Values of maximal power output and the load at which maximal power 
output occurs were determined from the power curves shown in Figure 3.9, and 
the errors in these parameters were determined from the least squares fit of the 
data. Parameters from the fit are summarized in Table 2. To compare power 
output between different myosins, all model fits are plotted on the same graph in 
Figure 3.10 and data points were removed for better visualization of the power 
trends.  
  N47K and R58Q FHC-linked mutations of the cardiac RLC caused a 
reduction in the maximal power output of myosin and the load at which maximal 
power occurs. Phosphorylation of the mutant RLCs restored power values to 
near WT myosin levels in the dephosphorylated state (Table 2). Phosphorylation 
 
Figure 3.9: Transformation of Data and Fits to the Hill Equation for Power 
Data from frictional loading motility assays was converted to load and power using Eq.2. 
Panels show the individual fits of the Hill power equation to the transformed data for 
each myosin. 
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of WT RLC resulted in a greater myosin power output, and a shift to slightly 
higher loads for peak power.  
 
 
 
Figure 3.10: Comparison of Myosin Power Output 
Fits of the power model are shown in the absence of transformed data, and isometric 
force values (± SE) estimated from frictional loading motility assays are shown on the x-
axis. RLC mutations and RLC phosphorylation exhibit contrasting effects on maximal 
power output and the load at which maximal power output occurs.  
Table 2: Loaded Parameters of Cardiac β-Myosin Predicted from Model Fitting 
 WT WT   Phos N47K 
N47K 
Phos R58Q 
R58Q 
Phos 
Max Power 
(aW) 
309  
± 93 
480  
± 81  
198  
± 57 
348  
± 95 
186  
± 53 
367  
± 117 
LoadM.Power 
(pN) 
1069  
± 112 
1368 
± 72 
698  
± 63 
1063  
± 122 
624  
± 51 
1029  
± 134 
Fo (pN) 2137      ± 224 
2736      
± 143 
1396     
± 126 
2126      
± 244 
1248      
± 102 
2058      
± 268 
Fd (pN) 1908      ± 259 
2644     
± 239 
1314     
± 159 
1992     
± 302 
1120      
± 110 
1817      
± 283 
Parameters ± SE from least squares fitting of loaded motility assay data. Maximal 
power, load at maximal power and Fo were determined from the model fits of Eq. 4. Fd 
was determined from the model fits of Eq. 3. Note: Fd values were included in the data 
sets that were fit to Eq. 4.  
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  The physiological range of loads experienced by the heart are assumed to 
be those spanning the region of maximum power output. Based WT myosin 
power curves in Figure 3.10, this range of loads corresponds to data points with 
α-actinin concentrations between 1.75-4.5 g/mL (the range is determined for 
power values greater than or equal to 70% maximum power). These data points 
were plotted and fit to Eq. 3 to compare myosin behavior in the physiological 
range of loads that it experiences (Figure 3.11). 
Figure 3.11: Model Fitting to the Physiological Range of Loads  
Nonlinear regression least squares fitting to Eq. 3 of the physiological range of α-actinin 
induced frictional load (left panels). Force values derived from the model with error bars 
given by the standard error of the coefficient from the least squares fit are shown in the 
bar graph. Force production was significantly reduced for N47K (p<0.05) and R58Q 
(p<0.02) myosin compared to WT myosin.  
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Curve fitting of the frictional loading model (Eq. 3) showed the same trend when 
comparing only the physiologically relevant loads as when comparing the entire 
data sets (Figure 3.6 and 3.10); however, R58Q dephosphorylated and 
phosphorylated myosin no longer exhibited a significant difference between 
isometric force values. 
 
3.4.4 Effect of Exogenous ADP on Loaded Velocity 
  Actin sliding velocity was measured under loaded conditions in the 
presence of ADP for myosin bearing WT and mutant RLC in the 
dephosphorylated and phosphorylated states. Average velocities were first 
determined in the absence of ADP with 1.5 μg/mL α-actinin load using an 
automated analysis. The same trends in velocities were observed for the 
automated data analysis as for the manual analysis of loaded motility assays. 
Actin sliding velocity was decreased for all myosins upon addition of 2 mM ADP 
to the motility buffer (Figure 3.12).  
  In the presence of ADP and α-actinin frictional load, N47K and R58Q 
myosin exhibited decreased sliding velocity compared to WT myosin (p<0.005), 
and phosphorylation of the mutant light chains restored velocity to WT levels. 
Interestingly, the motility of WT myosin was not altered by RLC phosphorylation 
in the presence of ADP. This is in contrast to the effect of RLC phosphorylation 
on loaded velocity in the absence of exogenously added ADP which acts to 
increase WT myosin velocity. This suggests that the presence of high levels of 
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ADP minimizes the effect of RLC phosphorylation under load for WT myosin but 
not mutant myosins. 
 
  
 
Figure 3.12: Effect of Exogenous ADP on Loaded Actin Sliding Velocity 
Shown are average actin sliding velocities (± SE) in the presence and absence of ADP 
under loaded conditions. Myosins bearing mutant RLC exhibit significantly reduced 
sliding velocity compared to WT myosin (p<0.005). 
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CHAPTER 4 – DISCUSSION AND PERSPECTIVES 
 
Introduction 
   In this work, in vitro motility assays were performed to study the effects of 
myosin regulatory light chain (RLC) phosphorylation and familial hypertrophic 
cardiomyopathy (FHC)-linked mutations on myosin contractility at the molecular 
level. Application of a frictional load in the assay allowed for the characterization 
of the load dependent behavior of porcine cardiac β-myosin bearing various 
RLCs. I found that RLC-FHC mutations, N47K and R58Q, reduced the isometric 
force and power output of β-myosin. On the other hand, phosphorylation of the 
RLC increased force production and power output for wild-type and mutant 
myosin. Phosphorylation of the mutant RLCs restored mutant-induced decreases 
in force and power to WT dephosphorylated levels. Myosin motors are the 
molecular machinery responsible for powering muscle contraction, therefore, it is 
expected that the changes in myosin properties described in this thesis, such as 
sliding velocity and force generation, ultimately lead to significant changes in 
cardiac muscle contraction. 
  Although amino acid point mutations in many of the various sarcomeric 
proteins result in FHC [35], the end stage disease is a product of several factors. 
It has been shown that each mutation displays a unique pathophysiology, and 
the prognosis of the disease depends on the specific causal mutation [156].  
Furthermore, in addition to the direct mutational effects on the single protein, the 
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disease phenotype could also stem from the culmination of altered protein 
interactions of associated proteins and/or compensatory mechanisms resulting 
from the original mutational defect. Often, physiological compensations that 
improve function eventually lead to effects that can ultimately be more 
detrimental than the initial effect of the mutation. RLC phosphorylation, a post-
translational modification, also exerts effects at the tissue level where it plays a 
role in fine tuning physiological processes such as the generation of cardiac 
torsion [123, 154]. Thus, small structural variations of the contractile proteins of 
the sarcomere appear to result in complex cascades of pathological or 
physiological effects that should be studied and understood at several levels of 
muscle organization in order to understand their molecular mechanisms and 
develop successful therapies. 
  Contractile properties of muscle can be studied using single molecule, 
muscle fiber, and tissue/organ techniques. Each technique has advantages and 
limitations that can be compensated for by the other experimental methods. For 
example, experiments using intact fibers permit the study of cellular based 
changes and probe the contractile properties of the myofibrillar lattice. However, 
causal and compensatory effects are harder to distinguish when studying higher 
order structures of muscle due to the complexity of the system. It is also hard to 
resolve which protein components specifically contribute to the observed effects. 
While it is more difficult to understand the molecular details and causation of 
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observed effects, higher order studies can better relate the consequences of 
mutations and post-translational modifications to global heart function.  
  The in vitro motility assay can be used to study the individual protein 
components involved in the contractile processes of muscle at the molecular 
level. The motility assay has the advantage of assessing the fundamental 
process that drives muscle contraction (i.e. the cyclical interaction of myosin 
motors that results in the sliding of an actin filament) while allowing the freedom 
to control solution concentrations in a precisely defined way. This approach is 
superior to solution biochemistry of actomyosin ATPase because it allows for the 
characterization of biochemical properties, as well as mechanical properties of 
the myosin motor as an individual force generator. For example, experiments 
presented in chapter 3 allowed for direct observation of the changes induced by 
RLC modifications on the properties of myosin. This bottom-up approach is 
valuable for understanding the molecular mechanisms by which FHC mutations 
and RLC phosphorylation exert their effect on myosin function. In addition, it aids 
the interpretation of the effects seen at higher order levels of muscle (e.g., 
transgenic mice studies) where compensations may cloud the original molecular 
defects, or contributions from various protein components may complicate the 
data interpretation.  
  In this section I will suggest and discuss potential molecular mechanisms 
by which FHC mutations and RLC phosphorylation alter myosin properties 
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(section 4.1), and then relate my findings to data from cellular and whole heart 
function studies performed by collaborators and others in the field (section 4.2). 
 
4.1 Molecular Effects of RLC modifications on Myosin Mechanochemistry 
  Data from motility assays are interpreted with velocity as a detachment-
limited process, first proposed by A.F. Huxley in 1957 [54]. This model assumes 
that each myosin acts as an independent force generator to move actin, and that 
myosin moves actin at a maximal velocity when there is at least one myosin head 
interacting with the actin filament at any given time. Actin sliding velocity, V, is 
limited by the detachment of myosin from actin, and given by: 
ܸ ൌ 	 ௗ௧೚೙ ൌ 	
ௗൈ௞ಲ೅ುೌೞ೐
௙    (Eq. 5) 
where d is the myosin step size, ton is the amount of time that myosin spends 
attached to actin, f is the myosin duty cycle (ton/tcycle), and kATPase is the actin-
activated ATPase rate (1/tcylce). Observed changes in actin sliding velocity can 
therefore be attributed to a change in one or more of these parameters. 
  Myosin containing mutant RLCs (N47K or R58Q) or phosphorylated RLC 
showed no difference in maximal unloaded sliding velocity compared to WT 
myosin (Figure 3.4). Unloaded measurements of the actin-activated ATPase 
activity also yielded no difference between myosins bearing various RLCs (Table 
3.1).  This finding was expected based on other documented studies in the 
literature which show that removal of the RLC from cardiac myosin [100] and 
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skeletal muscle myosin [72] have no effect on the actin-activated ATPase rate of 
the myosin in solution. Although unlikely, it is conceivable that a lack of effect on 
velocity could result from compensating effects on myosin step size and duty 
cycle. A former graduate student in the Moore laboratory, Michael Greenberg, 
found no differences in duty cycle of WT, N47K, and R58Q myosins when 
measuring actin sliding velocity as a function of myosin concentration [40], 
indicating that myosin step size is also unchanged by the mutations in unloaded 
conditions (Eq. 5). The lack of effect on unloaded activity in vitro is surprising 
given that the mutations lead to disease. However, since the heart operates 
under loaded conditions, observations of contractility in vitro working against an 
external load were required to reveal the mutant phenotype.   
  We introduced a load into the motility assay by the addition of surface 
bound α-actinin which transiently interacts with actin filaments gliding along the 
surface of a motility assay (see section 2.5.4).  As described in sections 3.5.2 
and 3.5.3 and figures 3.7-11, both RLC mutations and phosphorylation affected 
the actin sliding velocities measured from frictional loading motility assays, and 
ultimately myosin force and power output. Velocity, force and power are 
determined by the inherent kinetic and mechanical properties of the myosin 
motor. The force produced by a single myosin molecule is given by: 
ܨ௨௡௜ ൌ ݇ ൈ ݀   (Eq. 6) 
where k is the stiffness of the myosin cross-bridge and d is myosin step size. For 
ensembles of myosin, the force exerted depends on the number of myosin heads 
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bound to actin at any given time. Therefore the isometric force produced by an 
ensemble of myosins is given by: 
ܨ ൌ 	ܨ௨௡௜ ൈ ݂ ൈ ݊  (Eq. 7) 
where f is myosin duty cycle (fraction of the ATPase cycle that myosin spends 
strongly bound to actin) and n is the total number of myosin heads available to 
interact. In all experiments performed, n is held constant since the concentration 
of myosin on the surface remains the same. Therefore the changes induced by 
modifications to the RLC are due to an alteration in one or a combination of k, d, 
or f. Although myosin duty cycle and step size were unchanged by the RLC 
mutations for unloaded conditions, they may be altered in the presence of load 
since it is well established that exogenous load (or strain) can alter myosin 
kinetics [50].  
  Reduction in mutant motility was observed when a load was applied to the 
actomyosin in the in vitro motility assay. N47K and R58Q mutant myosins were 
unable to move actin as fast as WT myosin in the presence of an α-actinin 
frictional load, with decreases in actin sliding velocity being more prominent at 
higher loads. Model fits to the data using Eq. 3 demonstrated that the RLC 
mutations caused significant reductions in myosin isometric force.  
  One explanation for the lower force production of the mutant myosins 
could be decreased unitary force as a result of a reduction in stiffness of the 
myosin lever arm (Eq. 6). The RLC molecule sits at the base of the myosin lever 
arm, binding directly to the α-helical neck region of the myosin heavy chain at the 
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S1-S2 junction. This interaction mechanically stabilizes the lever arm and allows 
for the transmission of force from the myosin active site down the lever arm.  It 
follows that increased compliance in this region as a result of the RLC mutations 
would reduce the ability of myosin to transmit contractile force, consistent with 
our findings. In addition, solution studies using isolated RLCs showed that both 
mutations abolish calcium binding to the RLC [138, 139], indicating some degree 
of structural defects for the mutant RLCs, which could impact the lever arm 
mechanics where the RLC binds. In addition, previous studies from our 
laboratory have implicated a decrease in cross-bridge stiffness leading to 
reduced strain sensing ability for myosin bearing these mutations [41].  
  The reduction in loaded velocity seen for these mutations cannot be 
accounted for by an increase in compliance alone since actin sliding velocity is 
not directly dependent on cross-bridge compliance. Therefore, reduced velocity 
may stem from a decrease in step size or an increase in duty cycle. A change in 
myosin duty cycle would have competing effects on force and velocity, however it 
is plausible that increased compliance could result in dragging of the bound head 
and delayed detachment of myosin until all elasticity is pulled out of the cross-
bridge. This drag and prolonged ton would act to reduce velocity. The resulting 
increase in duty cycle would then require a large reduction in stiffness to 
significantly reduce the force generating capability of the mutant myosins. In 
addition, ATP is readily available to bind myosin in our assays and it is likely that 
ATP dependent detachment would limit the ability of dragging heads to prolong 
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attachment, especially at higher loads when actin sliding velocity is reduced and 
there is more time for ATP to bind before the elasticity is pulled out of the cross-
bridge.  
  A more likely scenario is that the observed decreases in loaded velocity 
result from a decrease in step size under load that accompanies the decrease in 
stiffness. A more compliant lever arm would be less effective at transmitting 
contractile force through the molecule leading to a smaller displacement of the 
actin filament (Figure 4.1). Accordingly, if binding of the N-terminal lobe of mutant 
RLC to the MHC neck α-helix is 
severely disrupted such that the neck 
α-helix becomes exposed to solvent, 
this could lead to a collapse of the 
helix thus shortening of the length of 
the lever arm, and decreasing myosin 
step size. Although less likely, it is 
also conceivable that the lever arm 
swing angle set by conformational 
changes in the converter domain 
could be affected by altered RLC interactions that propagate up the lever arm. 
Lever arm swing angle has been shown to vary depending on the myosin family 
member studied [65, 66], although these differences were associated with 
isoform specific differences in the converter rather than the light chain binding 
 
Figure 4.1: Effect of Lever Arm Stiffness
A stiffer lever arm is capable of transmitting 
greater loads, resulting in larger 
displacements of the actin filament as the 
load imposed on the actomyosin increases. 
Figure from Jeff Moore. 
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domain. A decrease in step size is more likely to stem from a lack of force 
transmission down the lever arm resulting from increased compliance of the 
hinge region. Thus, the effects seen here for N47K and R58Q RLC mutations are 
most likely accounted for by a decrease in k and d. 
  The effect of RLC phosphorylation on myosin motility under load observed 
here was opposite to the effect of FHC mutations on motility. Unlike the decrease 
in actin sliding velocity observed for the FHC mutations, velocity was increased 
across all loads for myosin with phosphorylated RLC, which reflects the 
corresponding increased force production. Whereas the FHC mutations may 
disrupt RLC interactions with the lever arm, reducing myosin stiffness, 
phosphorylation seems to do the opposite, possibly enhancing RLC binding and 
mechanically stabilizing the lever arm, ultimately leading to increased cross-
bridge stiffness and myosin step size. This interpretation is consistent with data 
from both unloaded and loaded motility assays when comparing 
dephosphorylated and phosphorylated RLC. In the unloaded case, RLC 
phosphorylation did not produce significantly different maximal velocity values 
from its dephosphorylated counterpart (with the exception of the R58Q RLC); 
however, it is evident that there appears to be a slight increase in unloaded 
velocity upon RLC phosphorylation (Figure 3.4). An increase in myosin step size 
is a likely cause of this subtle unloaded effect. The difference in unloaded 
velocity values approaches the resolving limits of the motility assay which makes 
it difficult to discern significance. Computational modelling of data obtained from 
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control and gene-targeted knock in mice with a nonphosphorylatable ventricular 
RLC found that in vivo data suggested the lever arm stiffness was increased via 
RLC phosphorylation [123]. In a separate study, the comparison between actin 
filament motility at low ATP concentrations to simulated step size data 
distributions found that RLC phosphorylation shifted porcine cardiac β-myosin to 
slightly higher step sizes [151].  It follows that phosphorylation of RLC is likely to 
have the inverse effect on lever arm stiffness and myosin step size when 
compared to the FHC-RLC mutations.  
  Phosphorylation of the mutant RLCs restored mutation-induced decreases 
in myosin contractility to WT dephosphorylated levels.  It is possible that RLC 
phosphorylation restores altered RLC-MHC interactions induced by the 
mutations. Isolated RLC studies on the R58Q RLC showed that phosphorylation 
restored its calcium binding ability and increased helical content of the mutant 
RLC [139]. This increase in helical content could explain the more resolved 
increase in unloaded velocity seen for the R58Q RLC upon phosphorylation.  
  The effects of RLC phosphorylation on force and velocity can be explained 
by an increase in stiffness and step size of myosin; however, in experiments 
where exogenous ADP was added to the buffer there was no observed increase 
in loaded velocity after phosphorylation of WT myosin as would be expected with 
an increased step size (Figure 3.12). The lack of an effect for RLC 
phosphorylation under these conditions might result from both load and 
exogenous ADP tending to increase the time that myosin remains strongly bound 
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to actin (ton). It may be that a subtle increase in step size is undiscernible under 
conditions where ton is greatly increased.   
  A second possibility for the lack of an effect of WT RLC phosphorylation 
under conditions of high ADP levels is that RLC phosphorylation affects the 
kinetics of the strongly bound states under load, and the presence of exogenous 
ADP attenuates this effect. ADP release is a load sensitive transition that is 
associated with an additional swing of the lever arm which results in a more open 
nucleotide binding pocket in the rigor state. RLC phosphorylation may shift the 
equilibrium towards the rigor state by accelerating the load sensitive ADP 
release, and stabilizing the rigor state. When exogenous ADP is added to the 
motility buffer it acts as a competitive inhibitor of ATP for the nucleotide binding 
pocket and slows velocity (Figure 3.12). The lack of an effect of RLC 
phosphorylation on WT myosin in the presence of high levels of exogenous ADP 
could be due to higher levels of ADP exchange with the nucleotide pocket due to 
a phosphorylation induced stabilization of the open binding pocket in the rigor 
state. This could explain the larger inhibitory effect of exogenous ADP on WT 
phosphorylated myosin compared to WT dephosphorylated myosin.  
  Results from our motility assays show that RLC phosphorylation 
mechanically alters the myosin molecule to make a more robust motor capable of 
transmitting greater loads at faster rates. This is functionally significant since the 
heart typically operates against a load imposed by diastolic blood pressure. 
Subtle changes to myosin velocity in the loaded in vitro motility assay and to the 
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force-velocity relationship lead to pronounced alterations in myosin power output. 
RLC phosphorylation increases myosin peak power and the load at which peak 
power is achieved. Phosphorylation of N47K and R58Q myosin restores 
mutation-induced decreases in force and power to near WT dephosphorylated 
levels. Changes in myosin power output are functionally significant because it 
affects the power output of the heart, which determines the rate of energy the 
heart can provide to meet its performance needs. 
Summary 
  The integrity of the lever arm is dependent on RLC binding [100]. While 
the RLC binds at a hinge region of the lever arm approximately 10 nm away from 
the myosin catalytic domain and actin binding site [106], RLC modifications alter 
myosin force production and velocity under load. The data is consistent with an 
interpretation where RLC modifications alter the stiffness of the lever arm. For 
FHC mutations this is most likely accompanied by a decrease in step size under 
load. For RLC phosphorylation this could result in increased step size and/or duty 
cycle. Without the use of single molecule techniques, it is difficult to dissect the 
precise molecular mechanism exerted by FHC mutations and RLC 
phosphorylation on myosin function. This topic will be discussed further in the 
next chapter. Nonetheless, it is intriguing to consider RLC phosphorylation as a 
therapeutic target for treatment of FHC resulting from N47K and R58Q RLC 
mutations given its restorative effects on RLC cation binding [139] and myosin 
force and power generation (Figures 3.7 and 3.10). 
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  By omitting the complexity that arises from the cellular environment, the in 
vitro motility assay permits observation of the direct effect RLC mutations and 
phosphorylation exert on myosin function. In combination with data from higher 
order muscle ensembles, one can begin to elucidate the pathogenesis and 
physiological consequences that result from small alterations at the molecular 
level. In the following sections I will discuss my findings in relation to data from 
muscle fiber experiments and in vivo studies. 
 
4.2 Higher Order Muscle Function 
4.2.1 Correlating RLC Phosphorylation Effects to Cellular and In Vivo Function  
  By applying a frictional load induced by α-actinin in the in vitro motility 
assay, we provided information about the load-velocity relationship for the 
interaction of myosin with actin. When comparing myosin containing 
dephosphorylated RLC (0% phosphorylation) and phosphorylated RLC (~85% 
phosphorylation), we found that phosphorylated myosin subtly increased actin 
sliding velocity at all loads measured, and significantly increased the isometric 
force production of myosin by 39%. This resulted in greater power output for 
myosin, with maximal power increased by 55% upon RLC phosphorylation. 
These experiments demonstrated that in the absence of thick filament assembly 
and calcium regulatory mechanisms, RLC phosphorylation affected isolated 
actomyosin mechanochemistry. 
  
105 
  The mechanical performance of muscle fibers is similarly altered via RLC 
phosphorylation. Skinned fibers from mouse trabeculae treated with MLCK 
exhibited increased steady-state force at rest and during maximal Ca2+ 
activation, indicating that the phosphorylation-induced increases in force were 
independent of calcium-activating mechanisms [23]. This is in agreement with 
our findings (Figure 3.8) which were performed in the absence of calcium and 
thin filament regulatory proteins. Recent studies on permeabilized trabeculae that 
were reconstituted with variably phosphorylated recombinant RLC showed a 
trend of increased force production with increasing levels of phosphorylation at 
saturating calcium [6]. This resulted in an upward shift of the force-velocity 
relationship and subsequent increase in power output, consistent with results of 
our work. In addition, increased phosphorylation of fibers resulted in significantly 
increased maximal shortening velocity as determined from slack tests [142]. 
While the same trends are observed in our work, the RLC phosphorylation in the 
fiber work was not as broad (~20-70%) yet the effects due to phosphorylation 
were much more pronounced, with a 3.7-fold increase in isometric force and a 
7.5-fold increase in maximal power [142]. This indicates that the phosphorylation 
induced changes in fiber mechanics are influenced by other cellular factors in 
addition to the contributions from the individual myosin molecule. For example, 
phosphorylation has been shown to alter thick filament structure such that 
myosin heads move away from the thick filament backbone, which in turn 
increases recruitment of myosin heads to the thin filament [23]. This thick 
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filament dependent process may increase the number of myosins bound and 
collectively increase force generation.  
  Increased maximal force generation and power output of muscle 
increases the total amount of work the muscle can perform. This property is 
crucial to phosphorylation dependent processes in the heart that require stronger 
contractions, or faster contractions under load. The effects of phosphorylation are 
not uniform in the heart because phosphorylation levels are present in a gradient 
pattern with higher levels in the epicardium [25, 48]. It follows that RLC 
phosphorylation is responsible, at least in part, for the enhanced performance of 
epicardial fibers needed to maintain cardiac torsion under basal conditions. In 
addition, an increase in work capacity conferred by phosphorylation would 
enhance the hearts ability to adapt to conditions of increased afterload.  
 
 
4.2.2 Familial Hypertrophic Cardiomyopathy-linked Mutations 
 
  FHC is characterized by a thickening of the left ventricular muscle or 
intraventricular septum, as well as myocyte disarray, and fibrosis. The pattern of 
cardiac remodeling varies with the genetic mutation. The RLC N-terminal 
mutations studied here, N47K and R58Q, are close to each other structurally but 
lead to different clinical phenotypes. In vitro motility assays, using porcine cardiac 
(PC) myosin, where the native RLC was exchanged with human ventricular RLC 
containing the N47K and R58Q mutations, showed reduced force production 
(Figure 3.8) and power output (Figure 3.10) of the myosin motor. 
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Relating In Vitro Motility Data to Fiber Studies and Clinical Phenotypes 
  We propose that N47K and R58Q mutations disrupt the sensitivity of 
myosin to load by changing the structure and mechanical properties of the α-
helical neck region of myosin.  Indeed, N47K and R58Q mutations disrupt the 
cation binding site leading to a loss of calcium binding to the RLC [138, 139]. 
Consistent with the decrease in force production observed in the motility assays 
in this work, measurements of skinned papillary muscle fibers from R58Q 
transgenic mice demonstrated a significant decrease in maximal force production 
[12, 152], while N47K transgenic mouse fibers demonstrated a minor decrease in 
force [152].   
  Reduction of actomyosin power is expected to impair the ability of the 
heart to eject blood. A mismatch in the power output of the FHC heart and the 
power needed to overcome afterload would reduce the ability of the heart to 
contract against the arterial blood pressure and would ultimately reduce cardiac 
output. Similar to the results observed here for isolated mutant actomyosin 
(Figure 3.10), measurements on isolated perfused working hearts from 
transgenic mice containing the N47K and R58Q mutations resulted in decreased 
cardiac power and cardiac output [1]. These mice showed hypertrophy with age 
and diastolic dysfunction, and while both mice had significantly impaired cardiac 
function the consequences of the R58Q mutation were much more profound. In 
addition, the R58Q mutation led to decreased levels of RLC phosphorylation 
before the onset of hypertrophy. [1].    
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  The R58Q mutation also presents with a more severe phenotype at the 
clinical level [60]. The N47K RLC mutation is associated with rapidly progressing 
mid-ventricular hypertrophy and diastolic filling abnormalities occurring late into 
adulthood, while the R58Q mutation is associated with left ventricular 
hypertrophy occurring during childhood leading to ventricular fibrillation and 
sudden cardiac death [6, 34, 60]. It is likely that the malignant phenotype 
associated with the R58Q mutation stems from decreases in the levels of RLC 
phosphorylation associated with the R58Q mutation [1]. Consistent with this idea, 
MLCK treatment of the R58Q RLC performed in this work resulted in less 
effective phosphorylation of the light chain compared with WT and N47K RLC, 
potentially due to altered substrate affinity for MLCK. Chemical modification of 
lysine and arginine residues within the regulatory light chain severely inhibited 
phosphorylation by MLCK [102], while chimeric light chains which altered the N-
terminal subdomains resulted in reduced reaction kinetics demonstrating that 
regions distal to the phosphorylation consensus sequence are important to 
MLCK activity [158]. It is conceivable that the loss of a positive arginine residue 
in the RLC N-terminal lobe could impair the ability of serine15 to be 
phosphorylated.  
RLC Phosphorylation as a Therapeutic Target  
  Here we show that phosphorylation of WT or mutant RLC increases force, 
suggesting an enhancement of myosin neck domain stiffness. Furthermore, it 
has been shown that phosphorylation of the mutant light chains can restore 
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calcium binding to the R58Q recombinant RLC [139]. Thus phosphorylation-
induced structural changes of the RLC likely affect its interactions with the 
myosin neck region and underlie the ability of phosphorylation to enhance 
myosin force and velocity under load, and restore these parameters of the 
mutant myosins to near WT levels.  A shift toward higher power and higher loads 
for peak power may be accomplished via RLC phosphorylation.  It is intriguing to 
consider phosphorylation as a drug target for alleviating symptoms in patients 
with RLC FHC mutations that exhibit reduced force generation.  
  Studies performed on another RLC FHC mutation, D166V, have also 
targeted RLC phosphorylation as a rescue mechanism for the mutation induced 
detrimental phenotype [90, 91]. In the tertiary structure of myosin RLC, the 
D166V mutation is predicted to be in close proximity to the RLC phosphorylation 
site [106]. Similar to R58Q, the D166V mutation resulted in decreased levels of 
RLC phosphorylation which likely contributed to decreased force production in 
skinned papillary muscle fibers from transgenic D166V mice [63, 91] and the 
malignant phenotype in humans [62, 110]. In the studies carried out by Muthu et 
al., a phospho-mimetic S15D was incorporated into the RLC [91].  This pseudo–
phosphorylation restored force production of the D166V myosin in the in vitro 
motility assay, similar to the rescue by RLC phosphorylation seen in this work. 
Similar results with phosphomimetic and MLCK-induced phosphorylation of the 
RLC suggests that it is the addition of a negatively charged residue that is 
responsible for the reversal of mutation induced effects.  
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  In addition to the reversal of mutation-induced effects at the molecular and 
cellular level, upregulation of RLC phosphorylation has also shown promising 
effects in vivo. Increasing the level of RLC phosphorylation in rodent hearts has 
been shown to improve cardiac performance during cardiac dysfunction. 
Overexpression of cMLCK resulting in increased phosphorylation levels was able 
to compensate for pressure overload and attenuate hypertrophy in mouse hearts 
[154] as well as improve cardiac performance post myocardial infarction in rat 
hearts [44]. These results are encouraging and suggest that regulation of RLC 
phosphorylation should be explored further as a mechanism to improve cardiac 
function. 
  Therapeutic strategies targeting RLC phosphorylation could be 
accomplished through upregulation of cMLCK, downregulation of myosin 
phosphatase, or the use of small molecule effectors that mimic phosphorylation. 
One possible way to upregulate cMLCK would be to inhibit ubiquitin protease 
which degrades cMLCK [154]. This would act to increase levels of cMLCK and 
has the added advantage of maintaining the native distribution of cMLCK in the 
heart. Successful downregulation of myosin phosphatase might target MYPT2, 
the protein subunit that binds type 1 phosphatase, PP1c-δ, to form the 
holoenzyme specific for myosin regulatory light chain [83, 97]. This would 
preserve the activity of the phosphatase for its other targets while specifically 
decreasing RLC dephosphorylation. Therapeutic interventions seeking to 
increase RLC phosphorylation may pursue a number of avenues; however the 
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best route will be one that preserves the gradient of RLC phosphorylation [25] 
and does not interfere with other processes in the heart. 
  The results from our motility assays show that RLC FHC mutations and 
phosphorylation have opposite effects on isolated cardiac myosin load-
dependent behavior. While N-terminal mutations disrupt myosin’s ability to 
produce force and power, phosphorylation of the RLC enhances myosin force 
and power production and is a mechanism that may be explored further as a 
potential therapeutic target. Follow up studies to the in vitro motility assays 
presented here may pursue two different directions, one which proceeds with 
single molecule techniques to dissect the precise molecular mechanism exerted 
by RLC N-terminal modifications on a single myosin motor, or one which 
proceeds with in vitro studies of higher order myosin ensembles to bridge the gap 
between the properties of isolated cardiac muscle proteins and cardiac muscle 
cells. In the next chapter I will discuss experiments that may be utilized in pursuit 
of both of these avenues. 
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CHAPTER 5 – FUTURE DIRECTIONS 
 
Introduction 
  The work presented in this thesis shows that cardiac myosin force 
production is altered by modifications of the RLC N-terminus. Continuation of this 
work might focus on dissecting the precise mechanism responsible for altered 
force production by directly measuring myosin stiffness (k), step size (d), and 
strongly bound time (ton). This can be accomplished using optical trapping 
techniques which can probe a single myosin interacting with an actin filament 
and provide high resolution measurements of the system. Another route might 
aim to bridge the gap between the contractile properties of isolated monomeric 
myosin and muscle fibers. In vitro assays that probe myosin assembled into thick 
filaments could explore the contributions of the thick filament backbone to myosin 
function and muscle fiber properties. In this chapter I will discuss potential 
experiments using optical trapping techniques and thick filament assays which 
aim to characterize a single myosin protein and the cooperative thick filament 
unit, respectively.  
 
5.1 Optical Trapping 
5.1.1 Basic Principles 
  Optical trapping is a technique that utilizes a tightly focused laser beam to 
hold microscopic particles stable in three dimensions. This phenomenon was first 
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described by Arthur Ashkin at Bell Laboratories whose group was able to trap an 
object with an index of refraction greater than the surrounding medium using a 
focused laser beam [8]. A light beam that passes through a particle with an index 
of refraction different from the surrounding medium is deflected according to 
Snell’s law. This results in a change of momentum of the light as it is refracted, 
which exerts a force on the particle due to the law of conservation of momentum. 
Light radiation from a laser imparts piconewton level forces to refractile objects 
by transferring momentum to the object when light is scattered or refracted by the 
object. Light with higher intensity will exert a greater force on the object as the 
light vector changes direction. A particle with an index of refraction greater than 
the surrounding medium is pulled toward the area of highest intensity (Figure 
5.1). 
 
Figure 5.1: Optical Trapping Force Diagram 
Light vectors are shown in dark red and the force exerted on the bead due to refracted 
light is shown with black arrows. The net force of the optical trap pulls the bead toward 
the beam waist. Forces from scattered light (not shown) apply an upward force on the 
bead in the direction the laser beam.  
Figure from https://en.wikipedia.org/wiki/Optical tweezers
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  A Gaussian beam exhibits a radial gradient of light intensity in the X-Y 
plane of the beam’s cross section with the most intense light at the center of the 
beam. Focusing the laser beam through a microscope objective creates a 
gradient of intensity along the Z-axis with the highest intensity at the beam waist. 
This allows a refractile particle to become trapped in three dimensions at the 
beam’s focal point.  
  Some of the light that is incident on the particle will be scattered rather 
than refracted. Scattered light rays exert a force on the particle in the direction of 
the light beam. In order to stably trap the particle, the forces exerted by the 
intensity gradient must be greater than the forces exerted by the scattered light. 
Therefore a microscope objective with a high numerical aperture is more 
desirable for optical trapping because it allows for a steeper gradient of light. 
When a particle is trapped it occupies a space just below the beam waist due to 
the force exerted by scattered light. The net gradient force exerted on the particle 
is linearly proportional to the particle’s displacement from the beam focus. The 
optical trap effectively acts as a Hookean spring with a characteristic stiffness 
that is proportional to laser power. The restoring force exerted by the trap on the 
bead is equal to ktrap*x, where ktrap is the characteristic trap stiffness and x is the 
displacement of the bead from the center of the trap.  
  The stiffness of the optical trap can be calibrated by three methods: the 
equipartition theorem, Stokes law, or the power spectrum method. All three 
methods depend on a statistical analysis of the motion of a trapped bead. 
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Sensitive photodiodes are utilized to measure the deflection of light from an 
object in the beam path which provides high resolution data of the object’s 
positon. The equipartition theorem states that an object in thermal equilibrium 
has the same kinetic energy associated with each translational degree of 
freedom, which is equivalent to ½kBT for one-dimensional diffusion. This kinetic 
energy is equivalent to the potential energy of the trap, which acts as a linear 
spring, and is given by ½*ktrap*<x2>, where <x2> is the variance of bead position. 
Therefore the trap stiffness can be determined by measuring the variance of a 
trapped bead.  The second method to determine trap stiffness uses Stokes law, 
which describes the drag force exerted on a small sphere that is moving through 
a viscous fluid. By moving a trapped bead at a known constant velocity through a 
medium of known viscosity, the Stokes drag force can be calculated and equated 
to the trap force. The effective spring constant (ktrap) can be solved by measuring 
the displacement of the bead from the center of the trap as it moves at constant 
velocity through the viscous medium. The final method for determining trap 
stiffness is the power spectrum method. The variance of bead position over time 
can be broken down into frequency components, and the power spectrum 
describes how the variance in position is distributed over frequency. When a 
force is acting on the bead this will give rise to a power spectrum with a 
characteristic corner frequency. Trap stiffness can be determined from the corner 
frequency. For a review of optical trapping principles and stiffness calibrations, 
see [116]. 
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  Laser based optical traps have made a significant impact in the study of 
biological systems by providing a method to apply and measure piconewton 
forces and nanometer displacements of microscopic particles. In most 
applications the optical trap is used to manipulate micron-sized polystyrene 
beads which are coupled to various biological membranes, organelles, polymers, 
proteins, DNA or whole cells. Optical trapping has been extensively used in the 
study of single molecules, most notably motor proteins [28, 100, 129, 141, 143, 
149].   
 
5.1.2. Optical Layout  
  An optical trap was designed around a Nikon Eclipse TE2000 inverted 
microscope in the Moore Laboratory. The excitation pathway consists of a solid 
state, 1064 nm Nd:YVO4 laser, five mirrors which guide the beam into the back 
aperture of the microscope, 12 lenses which expand the beam diameter, and a 
pair of acousto-optical deflectors (AOD) which steer the laser beam in the X-Y 
plane of detection with nanometer precision (Figure 5.2). The laser beam is 
collimated as it enters the back aperture of the microscope and becomes focused 
by passing through a microscope objective with a 1.3 NA. The diode laser that 
pumps the Nd:YO4 crystal is computer controlled. The user sets the current 
running through the diode laser which determines laser power; the laser has a 
maximum power of 4 watts. An AOD consists of a TeO2 crystal and a 
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piezoelectric device that generates sound waves within the crystal. The index of 
refraction of the crystal can be changed as a function of the sound wave 
frequency. The laser beam is deflected as it passes through the crystal 
generating a first order diffraction spot which can be moved in one dimension by 
altering the driving frequency. To steer the beam in two dimensions a second 
AOD is placed at a 90o angle to the first AOD, and the first order diffraction spot 
is deflected in a direction perpendicular to the first deflection. This creates a 
second order diffraction spot which can be manipulated in the X-Y plane and 
allows for precise control over the optical trap position. The radio frequency that 
drives the AODs and manipulates the laser beam position is computer controlled. 
By rapidly switching between two different frequencies the laser beam can be 
time-shared to create an additional second order diffraction spot, effectively 
creating two separate optical traps.
 
Figure 5.2: Optical Trapping Design 
A picture of the optical layout used for laser-based trapping in the Moore Laboratory.  
  
118 
  The design of the detection optics permits simultaneous bright field and 
fluorescence imaging while monitoring bead positon with high precision. The 
detection optics lie below the breadboard housing the trapping optics and collect 
light coming out of the side port of the microscope; it consists of a charge 
coupled device (CCD) for bright field imaging, an electron multiplying CCD for 
fluorescence imaging, and two quadrant detectors (QD) for high resolution 
measurements of bead position (Figure 5.3). The light coming out of the side port 
of the microscope is converging, therefore care had to be taken to ensure that 
each optical detector was aligned parfocal to each other, as well as to the focal 
plane at the side port of the microscope. This was accomplished by inserting a 
lens in the detection pathway, determining the distance from the lens that created 
a parfocal image plane with the side port image, and mounting each detector at 
this same distance from the lens. 
 
Figure 5.3: Detection Optics Schematic 
Light path for bright field imaging (CCD), fluorescence imaging (EMCCD) and high 
resolution position detection (QDs). Figure from http://amcc.uc.edu/2000.jpg 
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  A 1000nm short pass filter was placed in the detection pathway to block 
infrared laser light from interfering with the detection optics. A dichroic is used to 
reflect light below 650 nm to the EMCCD for fluorescence viewing. Finally, a 
pellicle beam splitter reflects 8% of the remaining light to the CCD to produce a 
bright field image of the trapped beads, and the remaining 92% of the light falls 
on the QDs (Figure 5.3).  
  A quadrant detector (QD) is a camera with four pixels, and the voltage 
output of each pixel is proportional to the amount of light that is incident on the 
pixel. An object in the light path of the quadrant detector will block light from 
reaching the quadrant detector and as the object moves the amount of light 
hitting each of the four pixels will change. The voltage output in the X and Y 
directions can be calculated by taking the sum and difference of pixels from the 
left and right sides, or top and bottom, to measure movement of the object with 
high precision.  
 
5.1.3 System Calibrations 
  Prior to performing experiments using the optical trap, three calibrations 
must be performed in order to analyze the raw data. Laser beam movements, 
trapped bead movements, and the stiffness of the optical trap must be calibrated. 
The beam position is controlled by a pair of AODs with the output given in units 
of MHz, and the position of a bead trapped in the beam is measured by the QD 
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with output given in units of volts. Therefore the software output for the AODs 
and QDs must be converted from MHz and volts to distance. This is 
accomplished using bright field images with a known pixel to nanometer 
conversion ratio. 
 
  To calibrate the AOD, the distance between two tightly trapped beads is 
determined from a bright field image and equated to the distance between the 
two trap positions given in MHz (Figure 5.4). The voltage output of the QDs must 
be calibrated in both the X and Y dimensions. To calibrate the QD, a trapped 
bead is moved across the QD in one dimension by stepping the AOD by a known 
amount. The QD has a narrow range where the voltage output is proportional to 
the change in MHz of the AOD position; experimental measurements must be 
taken within this range of the QD which corresponds to bead positions that lie 
completely within the boundaries of the four pixel detector. The average voltage 
change as the bead is stepped across the linear range of the QD is measured 
Figure 5.4: AOD Calibration 
AOD position is converted from MHz to nm using bright field images of trapped beads. 
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and equated to the AOD step size to determine the volts to nm calibration (Figure 
5.5).   
 
  The calibration of laser trap stiffness using the equipartition theorem is 
shown in Figure 5.6. The Brownian motion of a trapped bead is monitored, and 
the root mean squared displacement of the bead is used to calculate trap 
stiffness. The stiffness of the trap increases with laser power. It is important to 
measure the stiffness of the optical trap at the laser power that is used during 
experimental measurements. After performing all three calibration measurements 
experimental procedures may begin.  
Figure 5.5: QD Calibration 
The voltage readout of a QD as a trapped bead is stepped across the QD X-axis (Top 
Panel) and the corresponding AOD readout of laser trap position (Bottom Panel). The 
average bead displacement in the linear range of the QD given in volts is converted to 
nm using the previously determined MHz to nm conversion ratio.  
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5.1.4 Three Bead Assay 
  The three bead assay was originally developed in the Spudich Laboratory 
[32]. In this experiment an actin filament is attached to trapped beads and pulled 
taut to form a bead-actin-bead dumbbell. Nitrocellulose coated beads are firmly 
attached to the coverslip surface and act as a pedestal to raise myosin off the 
surface. The actin dumbbell is lowered over a bead pedestal which is sparsely 
coated with myosin, and a single myosin can interact with the suspended actin 
filament (Figure 5.7).  
 
Figure 5.6: Optical Trap Stiffness Calibration 
An optical trap behaves like a potential well, trapping a bead with a characteristic 
stiffness that can be calibrated using the equipartition theorem. The restoring force 
of the optical trap increases with laser power and the Brownian motion of a trapped 
bead becomes more constrained. 
  
123 
 
  The position of the actin dumbbell is monitored and the variance of the 
beads in the laser trap are calculated. When a myosin molecule binds to the actin 
filament the variance of the beads is reduced because the myosin molecule acts 
as an elastic linkage that dampens the Brownian motion of the dumbbell. Myosin 
binding events can be distinguished from Brownian motion due to the drop in 
variance. At low trap stiffness values, myosin can displace the actin filament as it 
binds and performs its powerstroke, which will displace the beads out of the 
center of the optical trap. This displacement is equal to the myosin step size, d. 
In addition, the drop in bead variance when myosin is bound can be measured 
over time to give the strongly bound time, ton.  
 
Figure 5.7: Illustration of the Three Bead Assay 
A diagram of the flow cell shows myosin sparsely coating bead pedestals attached to 
the coverslip surface, two laser-based optical traps, and a suspended bead-actin-bead 
dumbbell held in a position where a single myosin can interact with the actin filament.  
Figure from http://www.umass.edu/musclebiophy/techniques%20-20laser%20trap.html 
  
124 
 
  Myosin cross-bridge stiffness, k, can also be measured using the three 
bead assay. First the stiffness of actin linkage to the bead must be calibrated.  
This is done by oscillating one laser trap position and monitoring the 
displacements of both beads. The passive bead will have a smaller oscillation 
amplitude due to the series elasticity. The differences in amplitude of laser 
position, its trapped bead, and the passive bead, along with trap stiffness give a 
measurement of the dumbbell stiffness (kactin). Myosin stiffness is measured 
using these same parameters. When myosin binds to the actin filament it acts as 
an elastic element and shunts the oscillation of the dumbbell (Figure 5.9). The 
compliance of the myosin spring element can be calculated from the change in 
amplitudes observed upon myosin binding. The three bead assay allows for the 
measurement of single molecule properties using optical trapping techniques and 
is a valuable tool for studying molecular motors.  
Figure 5.8: Actin Dumbbell Linkage Calibration 
The stiffness of the actin linkage is determined by oscillating one optical trap and 
monitoring the position of both beads in the dumbbell.  
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  Myosin can be tested using the three bead assay to determine the 
mechanism by which RLC FHC mutations and phosphorylation alter myosin force 
production. RLC N-terminal modifications are likely to affect myosin crossbridge 
stiffness, therefore myosin should be tested using the experiment described in 
Figure 5.9. I would expect to see opposing effects of FHC mutations and RLC 
phosphorylation on measurements myosin stiffness. I predict that dumbbell bead 
oscillations would exhibit a greater amplitude during myosin attachment states for 
myosin bearing RLC FHC mutations which corresponds to a more compliant 
myosin crossbridge. Upon RLC phosphorylation I would expect the bead 
oscillations to have a smaller amplitude during myosin attachment which 
corresponds to a stiffer crossbridge linkage.  
  Myosin step size and strongly bound time can also be measured in the 
three bead experiment as mentioned above. For these measurements the actin 
dumbbell is positioned over a myosin coated bead and there is no oscillation or 
movement applied to the optical trap position (and dumbbell). The dumbbell will 
 
Figure 5.9: Sample Data Trace of Myosin Stiffness Measurement 
AOD and QD traces during a measurement of myosin stiffness show the oscillation of 
one laser trap of the actin dumbbell, and the response of the trapped beads (XR and XL; 
XL is the passive bead). Durations where myosin is attached to the dumbbell are denoted 
by a1-3, and correspond to dampened motion of the beads [148].  
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have an associated bead position and variance in solution, and these parameters 
will change when a myosin molecule binds to the dumbbell. A drop in bead 
variance indicates a myosin binding event, and myosin strong binding time can 
be determined by measuring the duration of the binding event. This should be 
done in conditions of high ATP concentration such that the availability of ATP to 
bind mysoin is not limiting myosin detachment. The change in dumbbell bead 
position in the absence and presence of myosin binding will give a measurement 
of myosin’s step size. I predict that myosin with RLC FHC mutations would lead 
to smaller displacements of the actin dumbbell, and that phosphorylation of the 
RLC would lead to larger displacements of the actin dumbbell. However, it is 
likely that changes in myosin step size would be difficult to resolve because the 
muscle myosin step size is less than 15 nm [67, 151] and alterations in step size 
would be on the order of a few nanometers which approaches the resolving 
power of our optical trapping system. The resolution of single molecule 
measurements is reduced by the random nature of myosin’s attachment to the 
bead surface. In addition, certain parameters such as the strongly bound time, 
ton, are expected to be greatly affected by myosin’s interactions with the thick 
filament backbone. These two variables can be better controlled by attaching 
myosin to a thick filament rod surface, which is discussed in the following section.  
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5.2 Towards Thick Filaments 
  Myosin is arranged in bipolar thick filaments in vivo. The RLC binds to the 
head-rod junction in a position where it is able to affect the ensemble state of 
myosin through interactions with the thick filament backbone as well as the 
mechanochemical properties of the individual myosin motor. In vitro thick filament 
assays provide an opportunity to distinguish between the effects exerted by RLC 
modifications on monomeric myosin versus thick filament ensembles of myosin. 
By adding complexity to our in vitro assays one step at a time, the system is well 
defined and myosin function from the single molecule to ordered ensembles can 
be characterized without complications that arise from other cellular components. 
  First I will describe potential experiments that explore how RLC 
modifications affect the function of a single myosin in a setting where the thick 
filament backbone is intact. Second I will describe experiments that characterize 
the emergent properties of myosin thick filaments. 
 
5.2.1 Contribution of Thick Filament Backbone to In Vitro Measurements 
  The contribution of the thick filament backbone to myosin function can be 
studied in the context of a single myosin which allows for the characterization of 
the myosin molecule in its native setting without characterizing the cooperative 
myosin thick filament ensemble. This can be accomplished through purification of 
the LMM fragment of myosin which forms the rod portion of myosin and is 
responsible for the oligomerization of myosin molecules in the thick filament. 
  
128 
Under favorable 
conditions the LMM 
protein fragments will 
assemble into thick 
filaments creating the 
thick filament backbone 
void of myosin cross-
bridges. Mixing a dilute 
amount of full length monomeric myosin with the LMM backbone results in the 
formation of a single myosin thick filament (Figure 5.10). Single myosin thick 
filaments can be used in place of full length monomeric myosin in the three bead 
assay described in the previous section. This would allow for a comparison of 
single myosin properties when myosin is randomly attached to a nitrocellulose 
coated surface versus when it is assembled in a thick filament backbone. Data 
from optical trapping assays where the filamentous backbone is preserved would 
provide valuable information about the contribution of myosin head-rod 
interactions to the inherent properties and function of myosin. Toward this aim, 
LMM was purified and assembled into thick filament rods as described below. 
  Soluble myosin is digested by chymotrypsin to purify LMM, based on the 
protocol of Lowey and Cohen [71]. Briefly, 10 mg/mL myosin suspended in high-
salt buffer (0.6 M KCl, 50 mM potassium phosphate, pH7.0) was mixed with α-
chymotrypsin diluted in 0.001 N HCl to a final concentration of 0.05 mg/mL. The 
 
Figure 5.10: Single Myosin Thick Filament 
Cartoon depicting an LMM thick filament backbone with a 
single full length myosin molecule attached.  
Adapted from http://users.atw.hu/blp6/BLP6/HTML/S3.htm 
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solution was stirred for 7 minutes and the reaction was stopped by addition of 0.5 
mM PMSF and dialyzed overnight against low-salt buffer (25 mM KCl, 20 mM 
potassium phosphate, pH7.0, 1 mM DTT). Following centrifugation at 111,000g 
for 1 hour the pellet containing undigested myosin and LMM was resuspended in 
high-salt buffer (Figure 5.11; lane 5). Three volumes of cold ethanol were added 
to the solution and stirred for 3 hours at 4oC to denature the undigested myosin. 
The precipitate was collected by centrifugation at 18,000g for 30 minutes and 
resuspended in high-salt buffer (Figure 5.11; lane 7). The solution was dialyzed 
against high-salt buffer with frequent changes to ensure the complete removal of 
ethanol. Following centrifugation at 111,000g for 1 hour the supernatant 
containing LMM was collected (Figure 5.11; lane 8) and dialyzed against low salt 
buffer. The precipitate was collected by centrifugation at 18,000g for 30 minutes, 
and the pellet containing purified LMM was resuspended in salt buffer, mixed 1:1 
with glycerol and stored at -20oC.  
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  Trial and error was used to determine favorable conditions for the 
formation of the filament backbone with LMM. The main determinant in this 
process is the salt concentration. Purified LMM at 0.1 mg/mL was dialyzed 
against myosin buffer, pH7.5 with varying KCl concentrations and then visualized 
via fluorescence microscopy (Figure 5.12). A monoclonal primary antibody to the 
ventricular β-myosin heavy chain that recognizes the LMM fragment was 
purchased from EMD Millipore (Billerica, MA, cat #MAB1552) and a polyclonal 
secondary antibody conjugated to TRITC was purchased from Abcam PLC 
(Cambridge, MA, cat #ab6725) for visualization of the LMM filaments.  
 
Figure 5.11: Purification of LMM Rod from Full Length Myosin 
A 12% SDS gel showing various purification steps of LMM starting with undigested 
myosin (Left), and a cartoon depicting myosin digestion sites and fragments (Right). 
Figure from http://www.cytoskeleton.com/media/wysiwyg/actinbind/myosindrawing.jpg 
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  At 300 mM KCl concentration, the LMM filaments have a fluorescence 
profile that is approximately 2-4 microns long (Figure 5.12). This is an 
appropriate size to use in the three bead assay. The only change to the three 
bead assay is that the nitrocellulose coated bead pedestals on the coverslip 
surface would first be incubated with filamentous LMM, followed by incubation 
with BSA in the same buffer to block the surface. Incubation with full length 
myosin would follow and also use the same buffer to ensure that LMM filaments 
do not disperse during the loading of the flow cell. Myosin is soluble when loaded 
into the flow cell and will bind to LMM filaments. After the formation of single 
myosin thick filaments on the flow cell surface the remaining buffer solutions can 
be composed at any salt concentration lower than the LMM buffer.  
  The use of single myosin thick filaments in the three bead assay described 
in section 5.1.4 would result in more consistent and accurate measurements of 
single myosin properties because the variability of myosin attachment to the 
surface would be eliminated and the myosin molecule would be probed in a more 
 
Figure 5.12: Fluorescence Microscopy of LMM Thick Filament Backbone 
The length distribution of filamentous LMM at differing [KCl] is visualized by binding of a 
TRITC-conjugated secondary antibody to the primary LMM antibody. 
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physiologically relevant environment.  In addition, the actin dumbbell may be 
aligned parallel to the LMM filament by fluorescently labeling the LMM rod which 
would allow the myosin molecule to interact with the actin filament in an optimal 
orientation. This would further reduce variability between single molecule 
measurements. 
 
5.2.2 Thick Filament Motility Assays 
  The work presented in this thesis focused on the characterization of 
monomeric myosin with various RLC modifications. Myosin is assembled into 
bipolar filaments in vivo and myosin molecules may cooperatively interact with 
each other to tune the function of the ensemble unit. In addition the RLC of 
myosin sits at the head-rod junction where it has the ability to influence the thick 
filament ensemble. Using myosin thick filaments in the in vitro motility assay may 
provide insight into the cooperative mechanisms employed by multiple myosins 
working in concert, and offers an opportunity to study how RLC modifications 
modulate myosin contractility in higher order structures.  
  Thick filaments can be reconstituted from monomeric myosin simply by 
lowering the salt concentration of the solution. Myosin will form thick filaments 
between salt concentrations of 100-200 mM, and in the pH range 6.5-8.0, 
however formation of a bare zone requires higher pH values closer to pH 8.0. 
Thick filaments are usually reconstituted either by directly diluting a sample of 
myosin, or by dialyzing myosin against a linear decreasing salt gradient. Myosin 
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concentration must be kept at or above 0.1 mg/mL for thick filaments to form. 
Once thick filaments have been reconstituted they can be used in place of 
monomeric myosin in the in vitro motility assay. Care must be taken to keep 
solutions at a salt concentration at or below that of the thick filaments to ensure 
the myosin ensemble does not disperse in the flow cell. Actin filament movement 
along bipolar thick filaments will proceed in a straight line, and will demonstrate 
two distinct populations of the actin sliding velocities. Actin filaments sliding 
towards the bare zone (favorable) will move at a faster velocity than actin 
filaments sliding away from the bare zone (unfavorable). In the in vitro motility 
assay with monomeric myosin randomly oriented on the coverslip surface, the 
actin sliding velocity measured is an intermediate value since the actin filament 
encounters myosin in a number of different orientations. Data from thick filament 
assays may clarify discrepancies seen between in vitro motility assays and 
muscle fiber studies. 
  In the unloaded motility assay, I would not expect to see differences 
between WT and mutant myosin thick filament motility since there was no 
difference between the monomeric myosins for any parameter tested under 
unloaded conditions. However, it is possible that the interactions of the mutant 
RLC with the thick filament backbone could affect the recruitment of myosin to 
the actin filament which in turn could affect thick filament actin sliding velocity. 
For myosin thick filaments with phosphorylated RLC, I would expect to see an 
increase in actin sliding velocity compared to dephosphorylated thick filaments. 
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Monomeric myosin with phosphorylated RLC showed slight increases in actin 
sliding velocity for unloaded conditions as well as across all loads tested, giving 
rise to an upward shift in the myosin force-velocity relationship, although a 
significant difference of such a subtle change could not be shown for one 
condition alone. This was interpreted as a phosphorylation induced increase in 
lever arm stiffness and subsequent increase in myosin step size, leading to 
significantly increased myosin force production with only a small increase in actin 
sliding velocity. In the setting of a thick filament where multiple myosins are 
optimally aligned and working in concert, I would expect this subtle change in 
actin sliding velocity to become more resolved. In addition, both thick filament 
structural studies and fiber studies support the idea that RLC phosphorylation 
increases the recruitment of myosin to thin filament by lifting the myosin 
crossbridge off the thick filament backbone surface [23, 69, 81, 98]. In muscle 
fiber studies, maximal shortening velocity was significantly increased as 
phosphorylation levels were increased from ~20% to ~70% [142], while 0% to 
~85% RLC phosphorylation of monomeric myosin only slightly increased actin 
sliding velocity in the experiments presented in this work. The effect of RLC 
phosphorylation on velocity was more than four times greater in muscle fiber 
experiments versus motility assays despite testing a smaller increase in the level 
of RLC phosphorylation. An increase in myosin recruitment or attachment rate 
with RLC phosphorylation could potentially explain the discrepancy in velocity 
values between these experiments. This effect of RLC phosphorylation is also 
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likely to be present in thick filament motility assays. I would expect the increase 
in actin sliding velocity between dephosphorylated and phosphorylated thick 
filaments to be greater than with monomeric myosin in the in vitro motility assay; 
however, this difference still may not be as great as in muscle fibers which have 
an intact filament lattice and multiple sarcomeres in series. 
 
5.3 Summary 
  In this thesis I explored the role of RLC N-terminal FHC mutations and 
phosphorylation in modulating cardiac β-myosin contractility. I characterized the 
load dependent behavior of myosin using in vitro motility assays with an applied 
frictional load exerted by α-actinin. Myosin bearing FHC mutations N47K and 
R58Q exhibited reduced actin sliding velocity under load resulting in reduced 
isometric force production of myosin. This subsequently led to a decrease in the 
maximum power output of mutant myosins as well as the load at which peak 
power is achieved. Interpretation of these results point to decreased compliance 
of the myosin lever arm as the cause of reduced mutant motility, which may also 
be accompanied by a decrease in myosin step size. Phosphorylation of the RLC 
had a contrasting effect on myosin load dependence, enhancing actin sliding 
velocity across all loads for WT and mutant myosins. RLC phosphorylation 
increased myosin’s isometric force production, maximum power output, and 
shifted myosin to higher loads for peak power. Phosphorylation of myosin 
bearing RLC FHC mutations restored the mutation induced defects back to WT 
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myosin levels. It is probable that RLC bearing FHC mutations have structural 
defects which may alter its interaction with the myosin heavy chain, and that 
phosphorylation may serve to restore these mechanical interactions. RLC 
phosphorylation shows promise as a therapeutic target for FHC-linked mutations 
of the RLC.  The precise mechanism by which RLC phosphorylation and FHC 
mutations work may be further dissected using single molecule optical trapping 
techniques, which could yield results that may aid the search for potential 
therapeutic interventions.  
  Results from our motility assays show that RLC phosphorylation 
mechanically alters the myosin molecule to make a more robust motor capable of 
transmitting greater loads at faster rates. RLC phosphorylation most likely exerts 
its effect by increasing myosin lever arm stiffness and myosin step size. In 
addition, studies where high levels of exogenous ADP were present suggest that 
RLC phosphorylation could potentially play a role in altering myosin’s strongly 
bound states by stabilizing the rigor state, though it is unknown whether this has 
any effect on ADP release rates or whether this would alter the time that myosin 
spends strongly bound to actin. It is important to note that myosin duty cycle is 
highly influenced by thick filament interactions and the lattice spacing of the 
sarcomere. Therefore the effect exerted by RLC modifications on this parameter 
is hard to predict at the cellular level based on observations at the protein level 
from motility assays where the contribution from these factors are not present. 
Thick filament assays could provide insight into the cooperative higher order 
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ensemble properties of myosin, and the contribution of RLC interactions with the 
thick filament backbone. Therefore, thick filament assays may be able to 
distinguish which effects of RLC modifications are more dominate in the native 
setting. 
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